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Summary  
Despite remarkable improvement since the implementation of angioplasty in acute 
treatment of myocardial infarction, long-term consequences of myocardial infarction, 
including heart failure, remain a challenge for modern medicine. Over the past decades, a 
need for an effective therapy to improve or rather to prevent adverse remodeling, and as a 
consequence prevent heart failure after myocardial infarction, remains unmet. To date, tested 
therapies have been aimed at various goals, including the prevention of cardiomyocyte death, 
reprograming cardiac fibroblasts into cardiomyocytes or cardiac progenitors, tuning immune 
responses, and modulating angiogenesis. Here we implemented a novel gene-cell therapy, 
combining the actions of two proangiogenic factors: VEGF-A and S1P delivered by ex-vivo 
lentivirus-infected bone marrow cells. Selection of the factors was based on their efficiency 
in inducing sprouting in an aortic ring assay. In the ischemia reperfusion model of 
myocardial infarction, bone marrow cells overexpressing hVEGF or hSphK1 were 
sequentially injected into mice at days 4 and 7 after myocardial infarction. 
Analysis of control and treated mice at 28 days post-ischemia reperfusion showed mild 
improvement in stroke volume, with no impact on ejection fraction in VEGF/S1P-treated 
mice. Adverse heart remodeling was decreased in treated animals, represented as a mild 
improvement in left ventricle systolic and diastolic volumes, prevention of cardiomyocyte 
hypertrophy, and better preservation of the ellipsoid heart shape. Moreover, sequential 
VEGF/S1P gene-cell therapy mitigated extension of the fibrotic scar. Analysis of immune 
response patterns in treated and control mice revealed distinct chemokine-receptor profile of 
circulating monocytes in the treated mice, suggesting their shift into a more reparative 
phenotype. Additionally, cardiac macrophages were less abundant in the remote zone of the 
mice injected with BMVEGF/BMSphK1. Finally, as primarily aimed, sequential delivery of 
VEGF and S1P resulted in increased capillary density, ameliorated adverse angioadaptation, 
and improved tissue oxygenation. Furthermore, the fibrotic index indicating myofibroblast 
abundance decreased in the infarct zone of hearts from treated mice. 
Our results identify a new strategy for sequential cell delivery of angiogenic factors to 
improve cardiac performance after myocardial infarction.   
Summary 
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Resumen  
A pesar de la mejora notable por la implementación de la angioplastia en el 
tratamiento agudo del infarto de miocardio, las consecuencias a largo plazo del infarto de 
miocardio, incluida la insuficiencia cardíaca, siguen siendo un desafío para la medicina 
moderna. En las últimas décadas, la necesidad de una terapia eficaz para mejorar o, mejor 
dicho, evitar una remodelación adversa y, como consecuencia, la insuficiencia cardíaca 
después de un infarto de miocardio, sigue sin cumplirse. Hasta la fecha, las terapias probadas 
se han dirigido hacia diversos objetivos, incluida la prevención de la muerte de los 
cardiomiocitos, la reprogramación de fibroblastos cardíacos en cardiomiocitos o 
progenitores cardíacos, el ajuste de las respuestas inmune y la modulación de la 
angiogénesis. Aquí, implementamos una nueva terapia de génica-celular, que combina las 
acciones de dos factores proangiogénicos VEGF-A y S1P administrados por células de 
médula ósea infectadas con lentivirus ex vivo. La selección de los factores se basó en su 
eficacia para inducir angiogénesis en un ensayo de anillo aórtico. En el modelo de isquemia-
reperfusión de infarto de miocardio, las células de médula ósea que sobreexpresan hVEGF 
o hSphK1 se inyectaron secuencialmente en los ratones los días 4 y 7 después del infarto de 
miocardio. 
        El análisis de los ratones control y los tratados 28 días después de la isquemia-
reperfusión mostró una mejoría leve en el volumen del latido sin impacto en la fracción de 
eyección en ratones tratados con VEGF/S1P. La remodelación adversa del corazón 
disminuyó en los animales tratados, representada como una mejoría leve en los volúmenes 
sistólico y diastólico finales del ventrículo izquierdo, la prevención de la hipertrofia de los 
cardiomiocitos y la mejor preservación de la forma elipsoide del corazón. Además, la terapia 
secuencial gen-célula VEGF/S1P mitigó la extensión de la cicatriz fibrótica. El análisis de 
los patrones de la respuesta inmune en ratones tratados y control reveló un perfil distinto de 
receptores de quimioquinas en los monocitos circulantes de los ratones tratados, lo que 
sugiere su cambio hacia un fenotipo más reparador. Además, los macrófagos cardíacos 
fueron menos abundantes en la zona remota de los ratones inyectados con BMVEGF/BMSphK1. 
Finalmente, y conforme al objetivo primario, la administración secuencial de VEGF y S1P 
dio como resultado un aumento de la densidad capilar, un menor angioadaptación adversa y 
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una oxigenación tisular mejorada. Además, el índice fibrótico que indica la abundancia de 
miofibroblastos disminuyó en la zona de infarto de los corazones de los ratones tratados. 
                Nuestros resultados identifican una nueva estrategia basada en el suministro 
secuencial de células productoras de factores angiogénicos para mejorar función cardíaca 
después de un infarto de miocardio. 
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1. Myocardial infarction and heart failure 
Cardiovascular disease (CVD) has been the leading cause of death in the US since the 
beginning of 20th century. In the US in 2014, 28.7% of male deaths and 22.3% of female 
deaths were caused by CVD. Almost half of these deaths were caused by coronary heart 
disease (CHD).  
Heart failure (HF) is the most common long-term consequence of CHD. Despite the fact 
that heart failure prevalence has increased from 5.7 million (2009 to 2012) to 6.5 million 
(2011 to 2014), the total number of deaths caused directly by CHD decreased by 19.2% 
between 2004 and 2014, in part due to an improvement in diagnosis and acute treatment of 
CVD1. 
One of the clinical manifestations of CHD is myocardial infarction (MI), defined as the 
sudden death of myocardial tissue from ischemia provoked by a blockage of a coronary 
artery, usually from an atherosclerotic plaque rupture2. After the onset of MI, a cascade of 
events occurs, including cardiomyocyte death, acute inflammation, angiogenesis and scar 
formation (Figure 1)3. Inflammatory and angiogenic responses in myocardial infarction will 
be further elaborated in this work (see subsections 1.1 and 1.2). 
Due to the limited ability of the adult mammalian heart to regenerate, the main healing 
mechanism after MI is through the formation of fibrotic scar2. Fibrosis causes abnormalities 
in both relaxation and contractility of the heart muscle. After myocardial infarction, 
accumulation of these pathological processes (e.g. cardiomyocyte loss, fibrosis and 
prolonged inflammation) leads to cardiac remodeling over time. 
Ventricular remodeling is either an adaptive or maladaptive mechanism of heart 
adaptation to adverse stimuli such as reduced contractility or/and increased wall stress 
caused among others by MI. The adaptive heart remodeling includes changes in the heart 
structure arising to sustain cardiac function, whereas maladaptive remodeling occurs during 
sustained stress and leads to irreversible changes in the geometry of the heart, resulting in 
abnormalities in its function4. Cardiac remodeling includes left ventricle wall thinning, 
ventricle dilation, and changes in the heart’s shape from ellipsoid to more spherical (Figure 
2).  
Introduction 
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Figure 1. Phases of healing after myocardial infarction.  Cardiomyocyte death, caused by 
ischemia, is followed by an acute inflammation phase. Signals are sent by dying cardiomyocytes 
mobilize monocytes and neutrophils to extravasate into injury site. Extracellular matrix is 
fragmented to facilitate cell migration and monocyte-derived macrophages ingest dead cells. Next 
step is formation of granulated tissue when process of angiogenesis occurs. Last phase is formation 
of scar tissue in to preserve ventricular integrity. Adapted from 3. 
 
On the cellular level, cardiomyocytes in the viable myocardium undergo hypertrophy 
triggered by increased load, which further leads to the abovementioned dilation of the left 
ventricle. These malformations create increasing wall stress on the beating heart, which 
causes further dilation, increase in the left ventricle end-systolic and end-diastolic volumes, 
higher myocardial oxygen demand, and could cause further increase of the area at risk for 
ischemia5.  
Heart failure is a clinical syndrome in which heart muscle is not able to maintain cardiac 
output (the amount of blood pumped by the heart over time) and, as a consequence, venous 
return. Ischemia caused by myocardial infarction is one of the main causes of HF together 
with hypertension and diabetes7. Pathological heart remodeling caused by MI and the 
secondary hypoxia, leads to HF over time8. 
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Figure 2. Ventricular remodeling after acute myocardial infarction. Healthy myocardium has a 
ellipsoidal shape, although over time after myocardial infarction it become more round, losing its 
contractile properties. This remodeling is a consequence of scar formation and maladaptation to 
overcome pressure load. When part of the ventricle contain scar tissue, which doesn’t contract, is not 
capable to pump blood properly. As a result, changes in geometry of the heart occur which finally 
result in further abnormalities in its function. Adapted from6. 
 
There are two types of heart failure: with preserved and decreased left ventricle ejection 
fraction (LVEF). Diastolic dysfunction occurs when LVEF is higher than 40% and systolic 
dysfunction when it is lower than 40%. Symptoms of diastolic and systolic HF are the same 
and include diminished cardiac output, which leads to global hypoperfusion and an increased 
amount of blood in the ventricle, which in turn increases end-systolic and end-diastolic 
volumes. These pathological changes lead to an increase in the LVEDP (left ventricle end 
diastolic pressure) and left atrial pressure as well as an increase in blood pressure in 
capillaries in the lungs, which causes pulmonary edema, the major clinical symptom of HF7.  
Depending on the patient’s age and comorbidities, the onset of HF may appear 
immediately after MI or be delayed.  HF has become the main cause of death of patients 
older than 65 years within 6 years after myocardial infarction9. For that reason, prevention 
and ameliorating the effects of HF seem to be of great importance.   
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1.1. Inflammatory response to myocardial infarction 
The immune system exists to defend the host organism against external pathogens, but 
also to promote tissue repair after so called ‘sterile inflammation’ like myocardial infarction.  
In healthy heart tissue, similarly to other organs, there are resident immune cells, mostly 
macrophages, usually situated near endothelial cells (ECs) or in the interstitial space10. There 
are also mast cells, which have an important role in the activation of early immune response, 
especially in the context of reperfusion during myocardial infarction11.  
Following the first phase of MI, which comprises cardiomyocyte death, a phase of acute 
inflammatory response begins. Necrotic and/or apoptotic cardiomyocytes release their 
cytosolic content (composed of damage-associated molecular patterns) into the extracellular 
matrix (ECM), which is sensed by the cardiac resident immune cells as well as non-immune 
cells12. The inflammatory response starts when activated cells start secreting cytokines and 
chemokines essential for recruiting leukocytes from the blood stream into the injury site13. 
Additionally, in the context of ischemia reperfusion injury, resident mast cells and 
complement proteins play an important role. Restoration of the blood flow after myocardial 
infarction by PCI (percutaneous coronary intervention/angioplasty) has become a common 
practice in the acute treatment of myocardial infarction. Even though blood flow restoration 
is crucial for rescuing still viable myocardium, it also causes amplification of the immune 
response. Complement proteins from restored blood flow enter the myocardium through the 
injured EC layer and trigger a proinflammatory response of the resident mast cells, which 
secrete mediators of inflammation like histamine and tumor necrosis factor (TNF)11. 
Furthermore, activated complement proteins attract neutrophils and facilitate their 
extravasation into the injured tissue.  
Neutrophils are the first innate immune cell subset recruited into the myocardium. 
Damaged cells release mitochondrial DNA and formylated peptides, which are structurally 
similar to bacterial components and therefore are sensed by neutrophils and promote their 
migration into the injury site. Furthermore, TNF and histamine secreted by mast cells 
activate endothelium and increase its permeability facilitating neutrophil infiltration into 
damaged tissue. Although neutrophils are crucial in the context of a pathogen-driven innate 
immune response, their protective role in sterile inflammation remains elusive; in fact, 
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proteases produced by neutrophils may aggravate the injury. Advantageously, neutrophil 
accumulation peaks at 24 hours after injury when they are phagocytized by 
monocytes/macrophages10.  
From the first day after MI, monocytes and their successors, macrophages, dominate in 
the cellular infiltrate of the ischemic heart. To describe recruitment of these cells, a biphasic 
model of monocyte/macrophage infiltration into the infarcted myocardium was proposed14 
(Figure 3).  
 
 
Figure 3. Monocyte recruitment 
to infarcted myocardium.  
First monocyte subset recruited to 
infarcted myocardium are Ly6Chi 
monocytes, sensing CCL2 released 
by damaged tissue. Ly6Chi 
monocytes take part in acute 
inflammatory response by removing 
debris, phagocytize neutrophils, and 
secrete proteases. During resolution 
of inflammation, second monocyte 
subset, Ly6Clow is recruited in 
response to CX3CL1. They secrete 
anti-inflammatory cytokines and 
take part in angiogenesis by 
secreting VEGF. Adapted from15. 
 
At first, in response to CCL2 released by the damaged tissue, a population of Ly6Chi 
inflammatory monocytes is attracted into the injury site. After a few days, the wounded heart 
switches to CX3CL1-dependent recruitment of Ly6C
low reparative monocytes; however, the 
mechanism of that switch remains unknown15. Although both monocyte subsets show the 
phagocytic phenotype, their role in the ischemic myocardium is distinct. As mentioned 
above, Ly6Chi dominate in the first 4 days post-MI and are rich in proinflammatory 
mediators. Their role in a recently injured heart is to digest infarcted tissue, remove debris, 
phagocytize neutrophils, and secrete proteases and matrix metalloproteinases. During 
resolution of the inflammation, the second phase, the Ly6Clow monocyte population takes 
over. Reparative Ly6Clow monocytes promote resolution of the inflammation by secreting 
anti-inflammatory cytokines: IL-10 and TGFβ. They also promote angiogenesis by secreting 
Introduction 
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vascular endothelial growth factor A (VEGF-A), stimulating collagen synthesis and 
deposition. Monocytes in the infarcted myocardium can play both protective and destructive 
roles, therefore coordinated cell recruitment seems to be crucial for proper healing14-16.  
Monocytes are also recruited to the remote myocardium, although to a much lower 
extent. Here, similarly to the infarct zone, they may be beneficial by promoting angiogenesis, 
but also harmful by promoting proteolysis of the collagen matrix. Excessive ECM 
proteolysis may facilitate left ventricle dilation by promoting interstitial fibrosis and/or 
secreting proinflammatory factors by activated fibroblasts15. 
In the long term, there are almost no monocytes in the infarcted heart. Instead, we can 
observe macrophages which, by being strictly linked with monocytes, may be either harmful 
or protective in the post-ischemic myocardium. As mentioned above, in a healthy heart there 
is a population of resident macrophages which help to maintain organ homeostasis. The 
population of macrophages present in the remote zone of an infarcted heart comes from both 
local proliferation and the recruitment of monocytes, which then differentiate into 
macrophages. It is well established that prolonged inflammation after myocardial infarction 
may aggravate the disease. In fact, it has been shown that activated macrophages of the 
remote zone take part in pathological left ventricle remodeling and development of heart 
failure. Mechanical strain which comes from the overloaded viable part of the myocardium 
may cause proinflammatory activation, as well as proliferation of the remote zone 
macrophages16,17.  
Monocytes/macrophages recruited to the ischemic heart are of both bone marrow and 
splenic origin. A large number of the initially recruited monocytes comes from the splenic 
reservoir. Subsequently, to meet the demand of the infarcted heart, cell production increases 
in the bone marrow and spleen triggered by the sympathetic nervous system and the release 
of noradrenaline in response to anxiety and pain at the time of MI event15. About half of total 
monocytes/macrophages recruited into infarcted heart come from the spleen origin. The link 
between them and heart failure was demonstrated using a mouse model of permanent LAD 
(left anterior descending) artery ligation where splenectomy reduced chronic HF events18. 
Thus, modulation of the inflammatory response after myocardial infarction is one of the 
therapeutic targets for HF treatment.  
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1.2. Angiogenesis in myocardial infarction 
During the third phase of MI, endothelial cells and fibroblasts proliferate and form a 
granulation tissue. During this process, there is an increased load on the viable myocardium, 
which might cause left ventricle free wall rupture and death. As a result of the healing 
process, a scar will be form in the place of granulation tissue and most of the ECs and 
fibroblasts will undergo apoptosis. Angiogenesis takes place in both infarcted and viable 
myocardium, and although most of the newly formed vessels in the granulation tissue will 
be lost during scar formation, neovascularization of the myocardium surrounding infarcted 
tissue might be a crucial factor to allow tissue salvage and to prevent heart remodeling which 
in turns leads to heart failure19.  
Sprouting angiogenesis is a process of the formation of new vessels from pre-existing 
ones in response to hypoxia, growth factors, nitric oxide and lipid mediators2 (Figure 4). 
When ECs are not supplied with oxygen (e.g. after MI), signaling through hypoxia inducible 
factors (HIF) upregulates many angiogenic genes, principally VEGF-A21. VEGF-A is the 
most important regulator of blood vessel formation and a member of a large family of 
angiogenic regulators, including PlGF, VEGF-B, VEGF-C and VEGF-D22. 
By binding to vascular endothelial factor receptor 2 (VEGFR2), VEGF-A promotes EC 
proliferation, as well as chemotaxis and differentiation of EC precursors. Adherent and tight 
junctions of quiescent ECs become dissolved and some of the cells within the capillary 
acquire a tip cell phenotype and start to lead a growing sprout (Figure 4). Tip cell phenotype 
is activated by expression of Dll4 (Notch receptor ligand) and activation of Notch signaling 
in surrounding (stalk) cells which prevents them from sprouting22. Extracellular matrix 
reorganization allows progression of the sprouts as well as prevents newly formed vessels 
from collapsing. Changes in the ECM composition provoke smooth muscle cell (SMC) 
migration and provide support to EC guiding them to their targets21. 
Formation of the lumen and the onset of blood flow helps to stabilize new vascular 
connections by improving oxygenation. Subsequently, hypoxia and VEGF-A related 
signaling become hindered, causing blockage of EC proliferation22. 
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Figure 4. Scheme of activation and maturation phases of angiogenesis process. Sprouting 
angiogenesis is a strictly controlled and chronologically organized process where new vessels are formed 
from existing ones. During activation phase, in response to VEGF and other signals, tight junctions 
between quiescent endothelial cells become loose and they start to proliferate. Sprout progresses 
following the tip cell, while extracellular matrix reorganization prevents it from collapsing. During 
maturation phase, onset of the blood flow helps to stabilize newly formed vessels and blocks hypoxia-
related VEGF signaling. Therefore, proliferation of endothelial cells is stops. ECM deposition causes 
migration of smooth muscle cells and pericytes, which help to form a stable vasculature. Many factors 
take place in maturation phase, including Ang1, PDGF and S1P. Adapted from20. 
 
To establish a functional vessel network, transformation of the newly formed vessels into 
more mature ones is essential. ECM deposition and recruitment of the mural cells (SMC and 
pericytes) and their interaction with the newly formed vessels regulates EC survival, vessel 
branching, blood flow and permeability. There are many factors participating in vessel 
stabilization, including platelet-delivered growth factor (PDGF), angiopoietins and lipid 
mediators like sphingosine 1-phosphate (S1P)23. PDGF is involved in vessel stabilization by 
recruiting PDGFRβ+ mesenchymal progenitors.  
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Angiopoietin 1 (Ang1) is a secreted glycoprotein and a member of angiopoietin growth 
factors family including Ang2, 3 and 424. Ang1 is a ligand of the Tie2 receptor, which is 
expressed on vascular endothelial cells as well as the proangiogenic monocyte subset 
identified by De Palma et al.25,26. Ang1 deficient mice die at an early embryonic stage due 
to disorganized and dilated vasculature networks27. During the maturation phase of 
angiogenesis, Ang1 activates the Tie2 receptor and promotes EC-mural cell interactions and 
the recruitment of pericytes21.   
Sphingosine 1- phosphate (S1P) is an important lipid mediator of cell growth, 
proliferation and migration in vitro. It also regulates angiogenesis, immune cell trafficking 
in vivo28 and is involved in cardiomyocyte protection in response to ischemia29. In 
angiogenesis, S1P plays a dual role: it promotes EC migration and, most importantly, takes 
part in the stabilization of newly formed vessels. Endothelial cell migration is mediated by 
the signaling from sphingosine 1-phosphate receptors 1 and 3 (S1P1 and S1P3). It was 
demonstrated in in vitro studies of 3D matrix cultures of endothelial cells, that S1P promotes 
lumen formation and EC branching morphogenesis30. On the other hand, S1P signaling 
through S1P1 is an important player in vessel stabilization; S1P1 gene ablation in mice 
impaired mural cell accumulation to the vessels during the maturation stage of 
angiogenesis31. After this discovery, it was shown that S1P mediates formation of N-
cadherin based junctions, which facilitate EC interaction between cells expressing this 
molecule, including other ECs and SMC, which is important for vessel stabilization32.  
Interestingly, the VEGF and S1P pathways seem to crosstalk in regulating angiogenesis 
and the vasculature. It was shown that VEGF treatment of bovine aortic EC induced 
overexpression of the S1P1 receptor on mRNA and protein levels. Furthermore, 
preincubation with VEGF increased subsequent S1P-dependent eNOS activation and 
phosphorylation in these cells as well as phosphorylation of Akt kinase, which is one of the 
kinases involved in the RISK pathway. The same study showed that VEGF pretreatment 
markedly induced S1P-mediated eNOS phosphorylation and vasorelaxation in isolated rat 
arteries. Therefore it was suggested that VEGF sensitizes vascular endothelium to lipid 
mediators via promoting overexpression of S1P1, which implies potential cross-talk in 
eNOS signaling pathways in the vasculature33. 
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2. Cell and gene therapies in myocardial infarction 
treatment  
The main treatment for myocardial infarction is acute coronary angioplasty ideally 
within 90 minutes door to balloon time in developed countries. This procedure involves 
inserting a catheter through the femoral or radial artery and, when the occlusion site is 
reached, inflating a balloon to restore blood flow and/or remove a thrombus. In some cases, 
implantation of a stent is necessary to prevent a vessel wall from collapsing34. Reperfusion 
of the coronary artery restores blood flow in the cardiac muscle and prevents further damage. 
Higher availability of this method correlates with lower morbidity of patients with STEMI 
(ST-elevation myocardial infarction) in which one of the main arteries is blocked35.  
Depending on the time between the first sign of MI to intervention, damage of the heart 
muscle may eventually lead to developing heart failure.  For that reason, there is a need to 
develop therapies aimed at reducing the area at risk or to ameliorate the pathological effects 
of MI (Figure 5). 
 
Figure 5. Strategies in treatment of myocardial infarction by promoting angiogenesis. Despite 
improvement in acute treatment of myocardial infarction, long term consequences remain severe and 
lead to heart failure. Over past decades, many strategies were developed to ameliorate effects of 
myocardial ischemia including recombinant protein therapies, gene therapies, cell therapies and 
combined gene cell therapies. All these approaches focus on a few main goals of post myocardial 
infarction therapies: improving angiogenesis, activation of adult cardiomyocyte proliferation, 
attenuating innate and adaptive immune response, and preventing cardiac cell apoptosis and necrosis. 
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One of the main strategies is to promote angiogenesis which, as mentioned above, takes 
part in endogenous healing of infarcted myocardium. Many different approaches were 
developed over time, including delivery of proangiogenic proteins directly or using various 
carriers, gene delivery using naked or encapsulated plasmids, as well as viral vectors. 
Another concept is to use various cell types, including unselected bone marrow-delivered 
mononuclear cells (BMMNC), as well as various purified cell populations like mesenchymal 
stem cells (MSC), endothelial progenitors (EPC) and many others. For the purpose of this 
work, only gene and cell therapy approaches will be further elaborated.  
 
2.1.  Cell-based therapies in treatment of myocardial infarction 
Cell therapies have primarily been based on the idea that stem cells present in the bone 
marrow are capable of differentiating into cardiomyocytes and replacing damaged ones. One 
of the first trials in a mouse model of myocardial infarction (by Orlic et al), showed improved 
myocardial contractility and the formation of new myocardium in the infarcted zone of the 
heart transplanted with Lin- c-kit+ cells36. Since then, many preclinical and clinical trials 
have been launched using heterogeneous cell populations as well as purified ones and the 
focus has turned towards the paracrine effect of these cells on infarcted myocardium. 
Therapies using bone marrow-derived mononuclear cells (BMMNC) have been tested in 
various clinical trials.  Accessible harvest and processing methods, as well as high yields, 
make them feasible for acute treatment of acute MI patients.  
The largest randomized clinical trial, REPAIR-AMI with intracoronary injection of 
BMMNC to the patients who underwent a PCI procedure, showed overall improvement in 
LVEF but there were no changes in end-diastolic volumes 4 months after intervention37. 
Additionally, there was decreased mortality in two years’ follow-up38. Another randomized 
clinical trial, BOOST, also showed short-term improvement in EF 18-months post-MI, but 
it was not confirmed in a 5-year follow-up39,40. Moreover, the ASTAMI second phase 
clinical trial showed no beneficial effect on global EF, left ventricle dimensions or infarct 
size at 4-6 months follow-up41. Meta analyses of 50 randomized and cohort trials on a  total 
of almost 3000 patients performed to unravel these mixed results showed a mild but positive 
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effect on the improvement of EF, decreased left ventricle-dimensions, and smaller infarct 
size42. 
Purified cell populations were also tested in various clinical trials, among them 
mesenchymal stem cells (MSC) of bone marrow and adipose tissue origin, cardiac stem cells, 
hematopoietic stem cells (HSC), as well as endothelial progenitor cells (EPC)43,44. 
Endothelial progenitor cells is a population of circulating cells of bone marrow, 
hematopoietic or adipose tissue origin, capable of proliferating, self-renewing and to 
repairing endothelial tissue. The exact definition of these cells remains controversial 
especially taking into account ‘early’ and ‘late’ subpopulations, although there are certain 
cell surface markers used to describe their phenotype including: CD34, VEGFR1, Tie2, vWF 
and CD11345,46.  
 The more broad population of CD34+ stem cells which includes both hematopoietic 
and endothelial cell progenitors have been used in various animal and clinical trials to induce 
angiogenesis in ischemic diseases including myocardial infarction47.  Autologous injection 
of CD34+ cells improved exercise time and decreased chest pain frequency in patients with 
refractory angina and no option for standard revascularization procedure, enrolled in 
RENEW clinical trial48. On the other hand, in the REGENT trial, patients with acute 
myocardial infarction followed by PCI, who received autologous injection of 
CD34+CXCR4+ cells, showed no improvement in EF 6 months after intervention49.  
 In parallel to cell therapy trials, gene-based approaches are also being investigated.  
 
2.2.  Proangiogenic gene-based therapies to treat myocardial 
infarction 
There are a few possible routes for gene delivery in cardiovascular therapies. From the 
most straightforward, using naked or encapsulated plasmids encoding desired genes, to more 
complicated with the use of adeno or lentiviruses (LV) (Figure 6). 
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Figure 6.  Tools used in gene therapies. To deliver therapeutic genes into host cells, many 
approaches are used, starting from most straightforward plasmid to more sophisticated viruses. 
Pros and cons of each method are presented.  Adapted from50. 
 
Because of their simplicity, plasmid-based approaches were used in many animal, and 
also clinical trials50,51. Intramyocardial injections of plasmids expressing VEGF in a sheep 
model of coronary artery ligation reduced scar size and improved perfusion but had no effect 
on global left ventricle function52. A plasmid approach using a proangiogenic VEGF gene 
was also used in clinical trials. There was no improvement in myocardial perfusion in 
patients with coronary artery disease after intramyocardial injection of plasmid VEGF during 
NORTHERN or EuroinjectOne trials53,54. A disadvantage in using plasmid vectors comes 
from the fact that they are cleared out of the circulation by nucleases. To overcome this 
obstacle, various encapsulation materials are used, including liposomes and polymers. 
Seeking a more efficient method for gene delivery, attention was focused on viral 
vectors, which in general have a higher translation efficiency than plasmid-based 
approaches.  
 In the Kuopio Angiogenesis Trial (KAT) clinical trial, patients with coronary heart 
disease received intracoronary delivery of Ad VEGF or plasmid liposome VEGF. A six-
month follow-up showed improvement in myocardial perfusion in the adenovirus-treated 
group, but no difference in exercise time between groups55. Adenoviruses (Ad) are capable 
of transiently transducing dividing and non-dividing cells within heart tissue, therefore they 
attracted attention for proangiogenic gene therapy where short term gene expression might 
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be beneficial. Especially serotype Ad49 seemed to be especially interesting, considering its 
increased transduction efficiency in EC and SMC56. On the other hand, these non-
integrating, non-enveloped vectors induce a strong inflammatory response which might 
influence transduction capability and utility in clinical setting because of safety reasons50.  
On the contrary, adeno associated viruses (AAV) cause much lower inflammatory 
response. Additionally, they provide sustained gene expression in the heart57. Similarly to 
Ad vectors, they provide episomal, nonintegrated expression of transgene. There are many 
serotypes of adenoviruses, also specifically cardiotropic after systemic delivery, like AAV1, 
AAV6, AAV8 and AAV958,59. In a porcine model of LAD ligation, intracardiac coinjection 
of two proangiogenic genes VEGF and Ang1 delivered using AAVs improved cardiac 
function (EF and LVESV) as well as myocardial perfusion at 8 but not 2 weeks after 
intervention60. The disadvantage of using AAV vectors comes from the fact that the time 
length of transgene expression is not controlled; therefore, it might have deleterious effects 
as shown for prolonged delivery of VEGF61,62.  
The last group of viruses used in research but to a lower extent are lentiviruses. Because 
of their ability to incorporate into a host genome of dividing and non-dividing cells, they are 
capable of transducing all cell types with long-term expression; but at the same time, there 
is a potential risk of insertional oncogenesis, especially when overexpressing proangiogenic 
genes63.  
 
2.3. Combined gene-cell therapies in MI treatment 
Knowing the advantages and limitations of both cell and gene therapeutic approaches, 
combined gene-cell therapies received attention. Since cell therapies seem to have only a 
mild positive effect on damaged myocardium, genetic modification of these cells, for 
example by overexpression of proangiogenic genes, might improve positive outcomes. At 
the same time, modifying cells in vitro allows for avoiding safety-related issues of direct in 
vivo gene delivery.  
Introduction 
35 
 
There are two strategies for gene-cell therapy. First, to genetically engineer cells in a 
way that changes their properties, for example, MSC overexpressing Akt to prolong their 
survival in an ischemic environment64.  
Secondly, to use cells as carriers of genes and allow secretion of a transgene in damaged 
tissue. In a rat model of ischemic cardiomyopathy, a comparison between the efficiency of 
direct injection of Ad-VEGF and skeletal muscle cells previously transduced with Ad-VEGF 
showed that only transduced cells improved heart function measured by fractional 
shortening. On the other hand, vascularization was enhanced in both groups65.  
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OBJECTIVES 
 
In the past decades, many approaches have been developed to improve heart function 
after ischemic damage. Many of them were focusing on improving angiogenesis, the process 
of formation of new vessels, which is a part of an endogenous healing process after 
myocardial infarction. Unfavorably, naturally occurring angiogenesis seems to be inefficient 
at significantly improving re-vascularization and preventing increased tissue damage, which 
results in pathological left ventricular remodeling and, over time, heart failure.  
In this work, we aimed at developing a combined gene-cell proangiogenic therapy. We 
hypothesize that sequential delivery of distinct proangiogenic factors would be beneficial to 
achieve a more functional vasculature. We decided to use a combined gene-cell therapy 
approach for both safety and efficiency reasons.   
To validate this approach we defined the following objectives: 
1. To design lentiviral vectors overexpressing proangiogenic or pro-vascular stabilizing 
factors and to evaluate the best proangiogenic combination of these factors in vitro.  
2. To establish a combined gene-cell therapy in a mouse model, and characterize its 
effect on the heart tissue at the functional and cellular level. 
3. To gain mechanistic insights into the effects of the combined therapy on the coronary 
microvasculature, inflammatory response and cardiac function and remodeling. 
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METHODS 
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Lentiviral vectors 
The human vascular endothelial growth factor (hVEGF-A165) gene was amplified using 
the human breast cancer cell line MDA-MB-231 as a template, with the following primers:  
 Fwd: 5’-CACTCGAGCCATGAATTTCTGCTGTCTTGG-3’,  
 Rev: 5’-CAGAATTTTGTCGATGGTGATGGTGT-3’.  
The proper band was extracted from the agarose gel using QIAquick Gel Extraction Kit 
(Qiagen) and cloned into pGEM®-T Easy Vector (Promega), with Quick-Stick Ligase 
(Bioline). Clones were selected by blue-white screening and after restriction analysis, 
sequenced and the proper sequence was confirmed with NCBI Nucleotide database. 
The human angiopetin 1 (hAng1) gene was amplified from a plasmid kindly provided by 
Prof. Kari Alitalo from the University of Helsinki using the primers  
 Fwd: 5’-CATTAATTAAGACCATGACAGTTTTCCT-3’,  
 Rev: 5’-CAGCGGGCGATGGATGATCCGTTGCTTT-3’,  
cloned into pGEM®-Easy Vector, selected by blue-white screening and restriction analysis 
and sequenced.  
The human sphingosine kinase 1 (hSphK1) gene was amplified from a commercially 
available plasmid pDONR223 (Changsha Yingrun Biotechnology Co. Ltd) using the primers 
 Fwd 5’-CATTAATTAATTGCAACAAATTGATGAGCA-3’,  
 Rev 5’-CAGCGGCCGCTCATAAGGGCTCTTCTGGCGGT-3’,  
cloned into pGEM®-T Easy Vector, selected by blue-white screening and restriction 
analysis, and sequenced.  
To clone the desired genes into the lentivirus backbone kindly provided by Dr. Mario 
Squadrito of the Ecole Polytechnique Federale Lausanne 
(p1031.8.pCCL.sin.SFFV.insert.WPRE). Each gene was amplified with primers containing 
AgeI and SalI restriction sites as well as START codon and Kozak sequence. Designed 
primers are summarized in Table 1. 
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Table 1. Designed primers 
Gene Primer Sequence 
hVEGF-A 
Fwd 5’-AAAAAACCGGTGCCGCCATGAACTTTCTGCTGTCTTGG-3’ 
Rev 5’-AAAAAGTCGACCTGTCGATGGTGATGGTGT-3’ 
hAng1 
Fwd 5’-AAAAAACCGGTGCCACCATGACAGTTTTCCT-3’ 
Rev 5’-AAAAAGTCGACGATGGATGATCCGTTGCTTT-3’ 
hSphK1 
Fwd 5’-AAAAAACCGGTGCCGCCATGTCCGCTCAAGTTCTGG-3’ 
Rev 5’-AAAAAGTCGACTCATAAGGGCTCTTCTGGCGGT-3’ 
GFP 
Fwd 5’-AAAGTCGACCAGTTAGCCTCCCCCATCTC-3’ 
Rev 5’-AAAACCGGTATCCACGCTGTTTTGACCT-3’ 
 
PCR products were purified using the High Pure PCR Product Purification Kit (Roche), 
digested with AgeI and SalI restriction enzymes, and the right bands were extracted from the 
agarose gel using the JETQUICK Gel Extraction Spin Kit (GENOMED). Subsequently, 
desired genes were cloned into the lentiviral backbone under a SFFV promoter using the 
Quick Ligation Kit (New England Biolabs). Clones were checked by restriction analysis 
using SalI and EcoRV as well as NcoI restriction enzymes and sequenced using the following 
primers:  
 Fwd 5’-AAGAATAGTAGACATAATAGC-3’,  
 Rev 5’-AAAGCAGCGTATCCACATAGCG-3’. 
To simplify, created vectors were named as follows: LV_hVEGF, LV_hAng1, 
LV_SphK1 and LV_GFP (Figure 7). 
The same genes were also cloned into a bidirectional lentiviral backbone provided by 
Dr. Mario Squadrito with the gene of interest under the PGK promoter and GFP (in case of 
hVEGF-A) and dNGFR (in case of hAng1 and hSphK1) under the CMV promoter, but they 
were not further used in this study.  
Lentiviral vectors were at first produced in-house using the protocol described in66. 
Briefly, VSV-G pseudotyped 3rd generation vectors were produced using the HEK293T cell 
line in a DMEM medium containing 10% FBS, penicillin (100U/ml), streptomycin 
(100U/ml) and glutamine. A plasmid DNA mix was prepared in the presence of CaCl2 0.25M 
final concentration, and HEPES buffered saline to form a precipitate. The virus was 
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concentrated by ultracentrifugation at 22.000 rpm for 2h at 22°C. Lentiviral vectors were 
resuspended in PBS and stored in aliquots at -80°C. 
 
 
Figure 7. Lentivirus vector maps of A. LV_hVEGF, B. LV_hAng1, C. LV_SphK1 and D. 
LV_GFP. 
 
Titration was performed by quantitative PCR analysis. Briefly, 200,000 HEK293T cells 
were seeded per well and infected with once-thawed viral vectors at 10-3, 10-4, 10-5, 10-6, 10-
7 serial dilutions. After removing the virus, cells were cultured for 7 days. Genomic DNA 
was isolated using Qiagen KIT.  
Once larger amounts were needed, viruses were produced by the Viral Vector Unit at 
CNIC. 
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Cell culture and bone marrow harvest 
HEK cells were cultured in DMEM medium (Gibco) with addition of 10% FBS (Sigma), 
2mM L-glutamine, 100U/ml penicillin and 100U/ml streptomycin (Lonza). 
Mouse bone marrow cells were harvested from 9-12 weeks old BL6 mice, or 
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo mice in the case of the cell homing experiment, by 
flushing femurs and tibias with cold PBS with the addition of 2% FBS. Red blood cell 
depletion was performed by adding sterile H2O miliQ on the cell pellet followed immediately 
with the addition of a large volume of PBS 2% FBS. Cells were cultured in density 2x106 
cells per ml on non-adherent plates in 199 medium (Lonza), 10% FBS, 100U/ml penicillin, 
100U/ml streptomycin in presence of murine cytokines: 20ng/ml M-CSF and 100ng/ml SCF 
(Peprotech). 
 
Bone marrow cell MOI experiment  
To investigate the best infection condition for bone marrow cells, freshly harvested BM 
cells were seeded in density 2x106 cells per ml on a 96 well plate in the final volume 300µl. 
Infection was performed overnight with SFFV_GFP virus MOI 100, 50, 25 and 12.5. The 
presence of GFP+ live cells was examined 24h, 3d and 6d after LV infection using FACS 
Fortessa (B&D).  
 
Real time PCR 
HEK cells were infected with a supernatant containing unconcentrated virus and kept in 
culture for a few passages. Subsequently, the cells were harvested and total RNA isolation 
was performed using the RNeasy Mini or Micro kit (QIAGEN), depending on the amount 
of cells. A reverse transcription reaction of 1µg of RNA was performed using the 
MultiScribe reverse transcriptase (High-Capacity cDNA Reverse Transcription Kit, Applied 
Biosystems) according to the manufacturer’s protocol, with the addition of an RNAse 
inhibitor (RNasin, Promega). A qPCR reaction was performed in the ABI PRISM® 7900HT 
FAST Real-Time PCR System using the SYBR®Green dye.   
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Mouse BM cells were infected with MOI 50 of corresponding LV. After overnight 
incubation, cells were washed with PBS and put back in the culture. 24h and 72h later, cells 
and supernatants were collected. Total RNA isolation, RT and qPCR were performed as 
described above for HEK cells. Experiments were carried out using three housekeeping 
genes in each approach. In the case of HEK cells, housekeeping genes were hHPRT, 
hGAPDH, 1433, and, for murine bone marrow cells, m36b4, mGAPDH, mTBP.    
All experiments included H2O sample as a template control, as well as untransduced cells 
as a negative control. Primers are summarized in Table 2. 
 
Table 2. Primers used for qPCR analysis  
 
Gene Primer Sequence 
hVEGF-A 
Fwd 5’-CTACCTCCACCATGCCAAGT-3’ 
Rev 5’-CTCGATTGGATGGCAGTAGC-3’ 
hAng11 
Fwd 5’-TCGTGAGAGTACGACAGACCA-3’ 
Rev 5’-TCTCCGACTTCATGTTTTCCAC-3’ 
hSphK12 
Fwd 5’-CATTATGCTGGCTATGAGCAG-3’ 
Rev 5’-GTCCACATCAGCAATGAAGC-3’ 
hGAPDH 
Fwd 5’-GGAGCGAGATCCCTCCAAAAT-3’ 
Rev 5’-GGCTGTTGTCATACTTCTCATGG-3’ 
hHPRT 
Fwd 5’-CCTGGCGTCGTGATTAGTGAT-3’ 
Rev 5’-AGACGTTCAGTCCTGTCCATAA-3’ 
hYWHAZ 
Fwd 5’-CCTGCATGAAGTCTGTAACTGAG-3’ 
Rev 5’-GACCTACGGGCTCCTACAACA-3’ 
mGAPDH 
Fwd 5’-AATGCATCCTGCACCACCAA-3’ 
Rev 5’-GTGGCAGTGATGGCATGGAC-3’ 
mTBP 
Fwd 5’-GCTCTGGAATTGTACCGCAG-3’ 
Rev 5’-CTGGCTCATAGCTCTTGGCTC-3’ 
m36b4 
Fwd 5’-GCGACCTGGAAGTCCAACTA-3’ 
Rev 5’-ATCTGCTGCATCTGCTTGG-3’ 
1PrimerBank ID: 21328452c2 
2sequence described in67 [61] 
 
ELISA 
To detect the presence of hVEGFa and hAng1 in the supernatants of cells previously 
infected with desired lentiviruses, R&D ELISA kits for these two proteins were used.    
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 Transduced HEK cells, as well as an untransduced control, were seeded on a 24-well 
plate in 0.5ml of OPTI-MEM medium (Gibco) with 1% FBS, 100U/ml penicillin, 100U/ml 
streptomycin. After approximately 30h incubation, supernatants were collected and kept in -
20°C. 
BM cells were incubated overnight with lentiviruses at MOI 50. After washing the virus, 
cells were seeded in a non-adherent 6-well plate at a density of 2mln/ml and the first 
collection of supernatant was performed 24h after. Next, cells were seeded back in culture 
and second supernatants were harvested after 48h and stored at -20°C.  
ELISA kits for hVEGFa and hAng1 were performed in proper dilutions according to the 
manufacturer’s instruction. Untransduced cells of both types served as a negative control 
and medium correction was performed using medium corresponding to each cell types. 
Optical density was determined using the Benchmark Plus microplate spectrophotometer 
(BIO-RAD) set at 450nm with wavelength correction at 540nm. Standard curves were 
created using CurveExpert software68. 
Plasma samples collected at three time points, t_0 (baseline, approximately one week 
before I/R), t_5 (24h after injection of BM_LV_hVEGF) and t_28 (endpoint), were analyzed 
for the presence of human VEGF-A protein using the Human VEGF-A Platinum ELISA kit 
(eBioscience, BMS277/2) according to the manufacturer’s instruction. Optical density was 
measured using the Benchmark Plus microplate spectrophotometer set at 450nm with 
wavelength correction at 620nm. Standard curves were created using CurveExpert 
software68. 
 
Blood and plasma sample collection 
Blood samples were collected from the facial vein of the mice (during experiment) or 
from aorta (at the endpoint) to EDTA coated tubes (Sarstedt Inc). Blood samples were used 
either for FACS analysis or for plasma collection. 
For plasma collection, samples were centrifuged at 2000g for 10 min, followed by a 
second centrifugation at 2500g for 15min. Subsequently, plasma samples were snap frozen 
in liquid nitrogen and kept in -80°C for analysis of S1P and hVEGF-A.  
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Flow cytometry   
To analyze peripheral blood monocytes, the flow cytometry technique was used. 
Blood samples were harvested into EDTA coated tubes and 100µl of each sample was placed 
into 1ml of 1X RBC Lysis Buffer (eBioscience) for 2-4 min, until the solution became clear. 
Subsequently, cells were washed with 9ml of ‘FACS buffer’ (2.5% FBS, 0.5mM EDTA in 
PBS) and centrifuged for 8min at 1200rpm. Blocking with 100µl of 1:100 Fc block (Mouse 
BD Fc Block, Purified Rat Anti-Mouse CD16/CD32) in FACS buffer was performed for 
20min at 4°C. Cells were washed with 2ml of FACS buffer and centrifuged for 5min in 
1200rpm. After that, cells were stained with 1ul/mln CD11b-Alexa fluor-647, 2µl/mln 
F4/80-PE-Cy7, 1.5µl/mln Ly6C-FITC, 2µl/mln CCR2-PE and 2µl/mln CX3CR1-Pacific 
Blue in 100µl of FACS buffer for 15min in RT protected from light. Washing with 2ml of 
FACS buffer and centrifugation for 5min in 1200rpm was performed. Cells were 
resuspended in 150µl of FACS buffer with addition of 5µl live/death dye 7-AAD (BD 
Pharmingen) per sample. Sample acquisition was performed using BD LSRFortessa. 
Single cell suspension from splenic tissue was obtained by pressing it through a 
100µm cell culture strainer (BD). Subsequently, red blood cell lysis and the rest of the 
procedure was performed as described above.  
Table 3. List of antibodies used for FACS staining 
Name Clone, company 
CD11b-Alexa fluor-647 M1/70, BD 
F4/80-PE-Cy7  BM8, Biolegend 
Ly6C-FITC  AL-21, BD Pharmingen 
CCR2-PE 475301, R&D 
CX3CR1-Pacific Blue SA011F11, Biolegend 
 
Aortic rings assay 
To assess the angiogenic response for various stimuli in vitro, the aortic rings assay 
described in69 was used. Briefly, aortas were dissected from 7-10 week old BL6 male mice, 
cleaned from fat tissue, and cut into approximately 1mm pieces. After overnight starvation 
in OPTI-MEM (Gibco), 2mM L-glutamine, 100U/ml penicillin, 100U/ml streptomycin 
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medium, rings were embedded in 1mg/ml rat tail Collagen type I (Merck Millipore) matrix 
in a 96-well optical plate at longitudinal orientation. OPTI-MEM medium with 2.5%FBS, 
L-glutamine, penicillin, streptomycin was added in the presence of various combinations of 
soluble factors (rhVEGF 30ng/ml, rhAng1 70ng/ml, S1P 1µM, Peprotech and Cayman 
Chemical) or mouse BM cells previously infected with lentivirus (BM_hVEGF, 
BM_hAng1, BM_SphK1). Ten rings per group were kept in the culture for 8 days and the 
medium was changed at day 4 and 6. Rings were rinsed with a PBS with ions and fixed with 
4% formalin (1.6%PFA) for 30min, RT. Afterwards, permeablization with PBLEC solution 
(PBS with ions, 0.1mM MnCl2, 1% Tween-20) in two 15min incubations at RT was 
performed, followed by blocking with DACO buffer (protein block serum free #X0909) 
30min at 37°C. 
Primary antibodies: IB4 (in the case of experiments with soluble cytokines) or hamster 
CD31 (in experiments using bone marrow cells) at concentration 1:150 and SMA-Cy3 
(1:400) in 50µl of PBLEC buffer per well were incubated overnight at 4°C on a nutator. 
After 3 x 15min washing with PBS 0.1% Triton-100, incubation with secondary antibodies: 
streptavidin-488 (1:200) or anti-hamster-647 (1:500) and Hoechst (1:10 000) was performed 
for 3h at RT. Rings were washed and embedded by adding 1 drop of Fluoromont to each 
well and kept in 4°C protected from light. Imaging was performed using Nikon A1R 
confocal system coupled to a Nikon Ti-Eclipse microscope using 10x objective and 
capturing 400µm in depth with z-stack every 3µm. Analysis of images was performed using 
a Matlab-based method for 3D-microvasculature developed in our lab, and using Imaris 
software. Antibodies used are summarized in Table 4 at the end of this chapter.  
 
In vivo experiment protocol 
Three days after I/R surgery, echocardiography under inhaled isoflurane anesthesia was 
performed to confirm myocardial infarction. Four days post I/R, mice were intravenously 
injected with 5x106 bone marrow previously infected with LV_hVEGF in 100µl of PBS or 
with PBS as a control group. 24h after first injection, blood samples were collected via facial 
vein. Seven days post I/R, a second injection was performed, with 5x106 BM cells infected 
with LV_hSphK1 and blood was collected 24h after injection. At day 28, endpoint 
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echography was performed and mice were sacrificed using a CO2 chamber. Blood samples 
were collected and hearts, lungs and livers were weighed and collected. Heart perfusion was 
performed through aorta using 5-10ml of cold PBS. Organs were immediately put in 0.4% 
PFA for overnight incubation at 4°C on a nutator. After washing with PBS, samples were 
incubated in 20% and 40% sucrose until they sank. For long-term storage, organs were 
embedded in OCT and kept in -80°C. 
 
Ischemia reperfusion in mice 
10-12 week old mice were pre oxygenated with 100% O2 for 5 min and anaesthetized 
with a combination of 10mg/kg Alfaxalone (Alfaxan®), 1mg/kg Medetomidine (Medeson®) 
and 2mg/kg Midazolam (Dormicun®). After thoracic fur trimming and application of a gel 
solution to avoid corneal drying, animals were intubated until they lost the pedal reflex and 
laid in right lateral recumbency, and chlorhexidine 1% was applied for skin disinfection. 
Mouse body temperature was maintained using a warmed 38ºC pad, and they were ventilated 
with 100% O2 (120 breaths per minutes 8ml/kg of tidal volume) using Minivent 680 
ventilator (Harvard apparatus). To reach the left ventricle of the heart, a 0.5cm skin incision 
was made over the projection of the 4th costal space. Without damaging left pectoral 
muscles, thoracic space was exposed between the 4th and 5th ribs. After a soft 
pericardiectomy, the left anterior descendent (LAD) coronary artery was visualized and 
occluded with a small piece of P10 fixed laterally with 7/0 nylon suture (Prolene®). LAD 
coronary artery reperfusion was allowed after 45 minutes, just releasing the suture and tubing 
pressure over the vessel. Reperfusion was confirmed after visualization of reddish heart 
color. Ribs and skin incision were sutured closed by planes with 6/0 silk suture. For recovery, 
2mg/kg of atipamezol (Revertor®) was inoculated IP and mice were extubated once they 
become conscious. To keep postsurgery analgesia, we inoculated SC with 0.1mg/kg of 
buprenorphine (Buprex®) and 320mg/kg of Paracetamol in drinking water for 3 days. 
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Lentiviral infection of bone marrow cells 
Bone marrow cells were isolated as described above and, after red blood cell depletion, 
were cultured overnight in 10ml of 199 medium, 10% FBS, 100U/ml penicillin, 100U/ml 
streptomycin in the presence of murine cytokines 20ng/ml M-CSF and 100ng/ml SCF on 
non-adherent petri dish. After overnight incubation, cells were counted using trypan blue 
and resuspended at 2mln/ml concentration. Desired viruses were added at MOI50 and 
incubated overnight at a 6-well non-adherent plate. Subsequently, cells were harvested and 
washed by adding a large amount of PBS 2% FBS to remove virus particles. After 
centrifugation, cells were resuspended in PBS 2% FBS, counted, washed again in ~40ml of 
PBS, and filtered through a 70µm cell mesh. The cell pellet was resuspended in PBS at 
concentration 100µl per 5x106 cells. 
 
Immunohistochemistry and immunofluorescence analysis    
Semi-3D sections of 15µm were cut using a Leica AM1950 automated cryostat and slides 
were stored long term at -20°C. For immunostaining, slides were washed in PBS for 5 min 
and permeabilized for 10min in 0.1% Triton in PBS at RT. Blocking in 10% BSA, 0.1% 
Triton in PBS was performed for 1h in a wet chamber at RT. Primary antibodies were 
incubated in blocking buffer overnight in a wet chamber at 4°C. After triple 10min washing 
with 0.1 Trition PBS, slides were incubated with primary antibodies for 1.5h in a wet 
chamber protected from light at RT.  Subsequently, slides were washed twice in 0.1% Triton 
PBS and once in PBS for 10min and mounted with Fluoromont G (Southern Biotech). 
For microvasculature staining, the primary antibodies hamster α-CD31 (1:150), rat α-
PDGFRβ (1:150) and α-SMA-Cy3 (1:400), the secondary antibodies goat α-hamster Alexa 
Fluor-647, chicken α-rat Alexa Fluor-488 (1:500), and Hoechst (1:10.000) were used. 
Images were acquired with a Leica SP5 confocal microscope using 40x objective (NA 1.25) 
with oil immersion. Z-stacks were acquired every 1µm. 
To quantify cardiomyocyte size and macrophage content, the primary antibodies rabbit 
anti-Laminin (1:50) and rat anti-CD68 (1:200), the secondary antibodies chicken a-rb-488 
and goat a-rat 568 (1:500), and Hoechst (1:10.000) were used. 
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Additionally, macrophage content was determined by immunohistochemistry staining to 
avoid autofluorescence in the infarct zone using anti-F4/80 antibody. CNIC’s Histology Unit 
performed immunochemistry staining and tissue was visualized using NanoZoomer-
2.ORS®, Hamamatsu. 
Fibrosis was assessed based on Masson-Tichrome staining and tissue was visualized 
using NanoZoomer-2.ORS® (Hamamatsu). 
In the homing experiment, tissue slices were stained with anti-RFP-594 antibody and 
Hoechst with 1:300 and 1:10 000 dilutions respectively.   
For 3D pig vasculature analysis, thick slices of approximately 100µm were cut using 
Leica AM1950 automated cryostat. Immunostaining  was performed in flotation using the 
following procedure: 2h permeabilization in 0.3% Triton, 0.1% Tween in PBS at RT; 1h 
blocking with 0:3% Triton, 4% FBS in PBS at 4°C.  For the staining of the microvasculature, 
slices were incubated with primary antibodies goat VE-Cadherin and mouse SMA with 
dilution 1:100 and 1:200 respectively in blocking buffer overnight at 4°C. After washing 
with 0.3% Triton in PBS, incubation with secondary donkey anti-goat Alexa Fluor-568, 
chicken anti-mouse Alexa Fluor-647 at 1:500 and Hoechst 33342, 1:10.000 (Life 
Technologies) was performed for 2h in blocking buffer at RT. After washing, slices were 
mounted on the glass using FluoromountG. All incubations were performed on the nutator. 
Antibodies used are summarized in Table 4. 
 
Table 4. List of antibodies/reagents used for immunostaining 
Name  Species Clone, company 
anti-goat-568 donkey Molecular Probes (A-11057) 
anti-hamster-647 goat Jackson ImmunoResearch (127-605-160) 
anti-mouse-647 chicken Molecular Probes (A-21463) 
anti-rabbit-488 chicken Molecular Probes (A-21441) 
anti-rat-488 chicken Molecular Probes (A-21472) 
anti-rat-568 goat Molecular Probes (A-11077) 
anti-RFP-594 rabbit polyclonal, Biotium (#20422) 
CD31 hamster 2H8, Merck 
CD68 rat FA-11, Serotec 
F4/80 rat CI:A3-1, Abcam (Ab6640) 
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Hoechst 33342 - Invitrogen (H1399) 
IB4-biotynylated - Vector Laboratories (B-1205) 
Laminin rabbit Sigma (L9393) 
PDGFRβ rat APB5, eBioscience 
SMA unconjugated  mouse 1A4, Sigma 
SMA-Cy3 mouse 1A4, Sigma 
streptavidin-488 - Invitrogen (S32354) 
Ve-Cadherin goat polyclonal, Santa Cruz (sc-6458) 
 
Image analysis 
Analysis of heart roundness was performed on images of the hearts after dissection using 
ImageJ software. Roundness was calculated as: 4 ∗
𝑎𝑟𝑒𝑎
𝜋 ∗ 𝑚𝑎𝑗𝑜𝑟 𝑎𝑥𝑖𝑠𝑥2
.  
To quantify cardiomyocyte size, ImageJ based semi-automated macro was designed. 
Cardiomyocytes recognized by surrounding laminin staining were quantified by area and 
perimeter. Subsequently, all images were revised by eye and incorrectly recognized ones 
were removed and/or labelled manually. 
Macrophage number based on CD68 immunofluorescence staining was analyzed using 
semi-automated ImageJ macro. At first, nuclei were recognized based on Hoechst staining 
and subsequently presence of CD68+ signal within a band surrounding nuclei was analyzed. 
Macrophages were defined as CD68+ cells and represented as a percentage of the total 
number of cells.  
Macrophage number based on F4/80 immunochemistry staining was analyzed using 
semi-automated ImageJ macro. Channels were separated using the color deconvolution 
plugin and similarly to the macro for CD68 immunostaining, macrophages were defined as 
a nuclei surrounded with F4/80 staining and represented as a percentage of total number of 
nuclei.  
All ImageJ-based macros were designed by Veronica Labrador Cantarero from CNIC’s 
Microscopy Unit. 
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Quantification of fibrosis was performed using ImageJ software on seven sequential 
15µm-thick cuts from the apex to the base of the heart.  Results are represented as a 
percentage of fibrotic tissue area to the left ventricle area.   
Analysis of the vasculature was performed using MATLAB-based 3D analysis method 
designed in our lab and described in detail in70. Capillaries were defined as CD31+ vessels 
of diameter < 5µm, estimated from previously made measurements in various species and 
tissues71-74. Medium-size vessels were defined as CD31+ vessels of diameter between 5.1 
and 8.7 µm. This category may constitute post-capillary venules as well as dilated capillaries 
compensating vasculature loss in response to injury. Large vessels (venules) were defined as 
CD31+ vessels of diameter > 8.7 µm based on literature74-77. Arterioles were defined as 
CD31+ SMA+ vessels independently of their size.    
 
Echocardiography 
Echocardiography was performed by an operator blinded to the study using a high-
frequency ultrasound system (Vevo 2100, Visualsonics Inc., Canada) with a 30-MHz linear 
probe. Mice were lightly anesthetized with 0.5-2% isoflurane in oxygen, administrated 
through a nose cone.  Echocardiography was acquired in supine position using a heating 
platform and warmed ultrasound gel to maintain body temperature. Standard two-
dimensional echocardiography (2D) and M-mode was performed in parasternal long axis 
view and parasternal short axis view. Images were acquired and analyzed later by a blinded 
expert using Vevo 2100 software. Cardiac parameters such as end-diastolic and end-systolic 
volumes, stroke volume and left ventricular ejection fraction were quantified using area 
length. 
 
Statistics 
Statistical analysis was performed using GraphPad Prism 6/7 software. Dependently of 
data being normally or not-normally distributed (defined using D'Agostino-Pearson and 
Shapiro–Wilk normality tests), parametric or non-parametric tests were performed. To 
compare two datasets, an unpaired t-test was used. A paired t-test was performed only to 
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analyze echocardiography-based progress of heart function of individual mice over time. To 
compare more than two datasets, one way ANOVA with Turkey’s test was used. P-values 
were defined as follows: *<0.05; **<0.005; ***< 0.0005, ****< 0.0001. Sample size (n) is 
indicated next to the each figure.  
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1. Ex vivo evaluation of combined angiotherapies. 
Aortic ring assay   
To analyze the effect of single or combined proangiogenic factors on its capability to 
induce sprouting, we decided to use the aortic ring assay, a model used to analyze angiogenic 
processes ex vivo78. 
1.1 Soluble factor approach  
At first, we sought to check the ability of single factors to induce angiogenesis; therefore, 
we cultured aortic rings in the presence of rhVEGF165, rhAng1 and S1P for 7 days (Figure 
8). VEGF is a strong inductor of angiogenesis, however it was shown that VEGF-induced 
vessels regress79 and leak80. Therefore, the use of a combination of angiogenic factors could 
be essential to establish a stable and mature vascular network. The use of VEGF, Ang1, and 
S1P in inducing angiogenesis was already described60,81-83, but to our knowledge they were 
not compared in simultaneous experiments to select for the best combination. Thus, our 
experimental setup consisted of two approaches.  The first being sequential delivery of 
factors where we use VEGF at day 1 of aortic ring assay and then after 4 days, an addition 
of either Ang1 or S1P. The second approach was prolonged delivery of VEGF and again 
addition of either Ang1 or S1P up until day 7 of assay whereby rings were fixed and stained. 
We then analyzed sprouting, using IB4 to stain ECs, and mural cell coverage, stained with 
αSMA.   
Among groups exposed to single factors, only treatment with S1P showed significant 
improvement in inducing sprouting (represented as volume occupied by endothelial cells 
stained with IB4) (Figure 9A) compared to non-treated rings and those treated with hVEGF. 
Within groups exposed to combined therapies, those with media containing S1P together 
with both sequential (3d) and prolonged (7d) hVEGF treatment, have significant 
improvement in sprouting compared control. Furthermore, treatment with hVEGF 7d + S1P 
4d significantly increased ECs volume density 6-fold compared to both groups with hVEGF 
+Ang1 treatment. Interestingly, any treatment including S1P improved aortic ring sprouting 
9-fold compared to non-treated groups and 5-fold when compared to VEGF alone. 
Results 
58 
Additionally, morphology of the sprouts differed. All aortic rings with S1P-induced sprouts 
created more complex vessel networks compared to the other groups (Figure 8).  
 
Figure 8. Proangiogenic efficacy of soluble factor combinations in aortic ring assay. Representative 
images of rings from each group. Collagen embedded rings were treated with single factors (hVEGF, hAng1 
or S1P) for 7 days. In the combined approach, rings were exposed to prolonged (7d) or sequential (3d) 
presence of hVEGF in combination with either hAng1 or S1P for 4 days. At day 7 rings were fixed and stained 
with IB4 and SMA antibodies. Maximal intensity projection, scale bar 200µm. 
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IB4+ endothelial volume parameter gives information about vascular volume, but not 
about their stability and maturation. Therefore, rings were co-stained with αSMA to 
determine mural cell coverage of vessels (Figure 9B).  In our setting, we observed in all but 
one group, no significant differences in the percentage of SMA covered sprouts. The hVEGF 
7d + S1P 4d combination group showed decreased mural coverage compared to both hAng1-
combined treatments.  
When summarizing both sprout abundance and their SMC coverage (Figure 9C), the 
two groups that show the best improvement in both categories are S1P alone and that with 
hVEGF 7d + S1P 4d combination, having no significant differences between them. 
 
 
Figure 9. Proangiogenic effects of various combinations of soluble factors on aortic rings 
assay. A. Quantification of IB4+ volume density. Rings were exposed for 7 days to either medium 
only or medium supplemented with indicated factors. Proangiogenic factors were added either 
alone or in combinations. B. Percentage of IB4+ sprouts covered with SMA served as a mural cell 
marker. C. Summarized representation of IB4+ volume covered and not covered with SMA. 
Kruskal-Wallis test. n=18±2 rings per group in two independent experiments. 
 
 
1.2 Effects of lentiviral-infected bone marrow cells 
overexpressing proangiogenic factors. 
After a broad screening process to select for the best combination of proangiogenic 
factors using commercially available hVEGF, hAng1, and S1P, we investigated whether 
bone marrow cells overexpressing chosen proangiogenic factors are capable of reproducing 
the same or similar phenotypes to those that we observed in the previous experiment.  
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1.2.1 Evaluation of lentivirus in HEK and mouse bone marrow cells 
We first checked the ability of cloned lentiviruses to transduce cells to overexpress and 
secrete desired factors. In the first approach, we used a HEK cell line because of its ability 
to be easily transduced.  
By real-time quantitative PCR, we observed a 100-fold change in expression of hVEGF, 
500-fold of hAng1 and over 300-fold of hSphK1 mRNA compared to untransduced cells 
(Figure 10B). Next, we wanted to check the ability of these cells to produce desired factors 
and to secrete them. For that reason, we collected supernatants from above transduced cells, 
and tested the concentration of either hVEGF or hAng1 by ELISA (Figure 10C, D).  In both 
cases, we observed increased amounts of protein compared to control, especially in the case 
of VEGF. A possible reason could be due to the fact that Ang1 protein is triple the size of 
VEGF and therefore, more difficult to secrete. In the qPCR experiment, we observed an 
increase in the mRNA levels of hSphK1 but as overexpression of the kinase does not 
necessary mean higher amounts of phosphorylated sphingosine, we checked the abundance 
of S1P in transduced and untransduced cells by mass spectrometry.  The results indicated an 
increase in LV_hSphK1 transduced cells (Figure 10E).  
Once we confirmed that the lentiviruses were inducing overexpression and secreting 
desired factors in HEK cells, we tested their efficiency in primary mouse bone marrow cells 
(msBM). 
As primary cells are notably more difficult to transduce84, therefore, we began by 
establishing the best Multiplicity Of Infection (MOI) to infect msBM using a LV_GFP 
lentiviral vector (Figure 10F). The highest percentage of GFP+ cells was observed with a 
MOI of 100, but it also resulted in a high mortality ratio; 47% of dead cells 6 days after 
transduction versus 26% with MOI50. Therefore, MOI50 was selected for further 
experiments. Similarly to HEK cells, we observed a higher secretion of hVEGF and hAng1 
by transduced msBM cells (Figure 10G and H) as well as an abundance of S1P (Figure 
10I).  
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Figure 10. Evaluation of lentiviral vectors in HEK and msBM cells. A. Real-time quantitative PCR 
of hVEGFa, hAng1 and hSphK1 genes overexpressed in LV infected HEK cells compared to 
untransduced cells. B. mRNA fold change of gene expression. C.-D. ELISA of hVEGFa (C) and hAng1 
(D) secretion in supernatants of LV-transduced HEK cells. E. Abundance of S1P in LV_hSphK1-
transduced and untransduced HEK cells.  F. Percentage of GFP+ mouse bone marrow (msBM) infected 
with different MOI of LV_GFP lentivirus at different time points after LV-transduction. G.-H. ELISA 
of hVEGFa (G) and hAng1 (H) secretion by LV-infected msBM cells 48h and 72h post infection. I. 
Abundance of S1P in LV_hSphK1-transduced and control msBM. qPCR: n=3 with 3 technical replicates 
each, in tree independent experiments. ELISA: n=6-7 in four experiments for HEK cells and n=4-5 in two 
experiments for msBM cells. S1P measurement: n=3 for HEK and n=2 for msBM cells with 3 technical replicates 
in one experiment. MOI test: n= 4 in two experiments. t-test (two samples)/one-way ANOVA (three samples). 
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1.2.2 Effect of BM cells overexpressing proangiogenic factors in the 
aortic ring assay  
Once we confirmed that msBM infected with the lentiviruses were capable of secreting 
soluble proangiogenic factors, we tested if they could induce sprouting in vitro. 
In this approach, aortic rings were cultured with hVEGF_BM for 3 days followed by 
hAng1_BM or hSphK1_BM for 4 days (Figure 11). Control groups were cultured only with 
medium or with WT_BM. At day 7, rings were fixed and stained with CD31 for endothelial 
cells, and αSMA for mural cells.  
 
 
Figure 11. Aortic rings experiment using lentiviral-transduced bone marrow cells. Representative 
images of rings from each group. Collagen embedded rings were cultured in the presence of wild type BM 
cells or BM cells overexpressing hVEGF (BM_hVEGF) in combination with either BM_hAng or 
BM_hSphK1. Maximal intensity projection, scale bar 200µm. 
  
 
Similarly to results seen in experiments with soluble factors, a combination of msBM 
overexpressing VEGF with SphK1 increased CD31+ volume density (Figure 12A). We also 
observed a significant decrease in SMC coverage in hVEGF_BM + hSphK1_BM group 
(Figure 12B). This result is similar to that observed in the soluble factor approach where the 
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group of S1P with prolonged (7-day) exposure of VEGF, but not 3 days, showed impaired 
mural cell coverage. Here, even though we were delivering cells sequentially, BM cells 
overexpressing VEGF could have migrated into the collagen matrix and kept secreting 
VEGF. Nevertheless, combined hVEGF_BM + hSphK1_BM treatment yielded overall 
higher number of sprouts covered by SMA compared to the other groups (Figure 12C). 
 
 
Figure 12. Proangiogenic effect of lentivirally infected bone marrow cells secreting soluble 
factors. A. Quantification of volume occupied by CD31+ cells in aortic rings cultured for 7 days 
in the presence of medium, wild type bone marrow cells or bone marrow cells infected with 
LV_hVEGF in combination with either LV_hAng or LV_SphK1. B. Percentage of CD31+ sprouts 
covered with SMA (mural cell marker). C. Representation of CD31+ volume covered and not 
covered with SMA in each group. Kruskal-Wallis test. n=25±2 rings per group in three 
independent experiments. 
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2. Proangiogenic gene-cell therapy in ischemia/ 
reperfusion murine model of myocardial 
infarction  
Experimental design 
In light of in vitro results, we implemented a therapy to improve angiogenesis after 
myocardial infarction in a mouse model of 45-minute occlusion of the left anterior 
descending artery followed by reperfusion (Figure 13).  
 
Figure 13. In vivo experimental design.  
 
In the ex vivo approach, treatment of aortic rings with the combination of BM_hVEGF 
followed by BM_hS1P resulted in the highest amount of sprouts. Although the same 
combination showed decreased mural cell coverage, it remained close to 60%. Based on 
these results and taking into account the cardioprotective activity of S1P, we decided to use 
BM_hVEGF + BM_SphK1 combination in the in vivo setting.  For that, bone marrow cells 
were isolated and infected with lentiviruses to overexpress hVEGF or hSphK1. Three days 
after I/R, echocardiography was performed to confirm myocardial infarction. At day 4 mice 
were randomly divided into control and treated groups, and injected intravenously with 
either PBS or 5x106 of LV_hVEGF BM cells respectively. At day 7 post-I/R, mice from 
treated group were injected with 5x106 of LV_hSphK1 BM cells and controls with PBS. At 
28 days after myocardial infarction, endpoint echocardiography was performed, mice were 
sacrificed and organs collected for histological analysis. Blood samples were collected at 
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basal condition (~1 week before I/R), 24h after first and second i.v. injection, 14 days post-
I/R and at the experimental end point.  
 
2.1 Phenotype of lentivirally-infected bone marrow cells 
In our experimental setting, bone marrow cells were lentivirally infected to secrete 
therapeutic proangiogenic factors: hVEGF and S1P (by overexpression of hSphK1).  
 
 
 
 
Figure 14. Characterization of lentivirally transduced bone marrow cells used for 
intravenous injection. A.-B. Gating strategy and representative plots of basal (A) and lentivirally 
infected bone marrow cells (B). C. Changes in CX3CR1 and CCR2 receptors expression on 
monocyte subpopulation between wild type and lentivirally infected cells  with both LV_hVEGF 
and LV_SphK1. 
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After infection, cells were harvested and intravenously injected into mice which had 
undergone a myocardial infarction.  
To characterize whether lentiviral infection of msBM change their phenotype before 
injection, we analyzed them using flow cytometry. Prior to lentiviral infection, cells were 
cultured in the presence of M-CSF and SCF, which tends to shift their phenotype towards 
myeloid lineage85. This lineage includes, among other, the monocyte/macrophage and 
neutrophil populations. Therefore, at first, these populations were discriminated based on 
SSC/FSC plot (Figure 14A, B). Neutrophils were defined as CD11b+ F4/80- Ly6Cmid SSChi. 
Monocyte/macrophage subpopulation was further divided into macrophages (CD11bhi 
F4/80+), monocytes (CD11bhi F4/80-Ly6Chi) and myeloid progenitors (CD11b+ F4/80-  
Ly6Clow). Because of the role of chemokine receptors in monocyte homing, expression of 
CX3CR1 and CCR2 receptors on the monocyte subpopulation was also determined in wild 
type (WT) and lentivirally-transduced bone marrow cells using median fluorescence 
intensity (Figure 14C).  
As expected, monocytes constituted a majority of live cells (nearly 60%) (Figure 15D). 
Approximately 1% of live cells were myeloid progenitors (Figure 15C). Even though we 
did not observe differences in the size of monocyte population between infected and non-
infected cells, we observed an increase of CX3CR1 expression after LV infection. 
Furthermore, cells infected with LV_hSphK1 expressed more CX3CR1 than the ones 
infected with LV_hVEGF (Figure 15D). In the case of CCR2 expression, we did not see 
any changes between groups (Figure 15C).  
Both LV_hVEGF and LV_hSphK1 infection significantly decreased the amount of 
macrophages present in the bone marrow cell culture from 6% of live cells to less than 1.5% 
(Figure 15A). Conversely, there was an increase in the neutrophil population, from 3% in 
wild type cells to 6% in cells infected with LV_hVEGF and a slightly higher percentage 
(7%) after LV_hSphK1 infection (Figure 15B).  
 
Results 
67 
 
 
Figure 15. Quantitative representation of bone marrow subpopulations infected with 
lentivirus. Bone marrow cells were cultured in the presence of M-SCF and SCF which shifted 
their differentiation into the myeloid lineage. A. Percentage of the macrophage population defined 
as CD11bhi F4/80+. Neutrophils were defined as CD11b+ F4/80- Ly6Cmid SSChi (B). C. Percentage 
of myeloid progenitors defined as CD11b+ F4/80-  Ly6Clow. D. Percentage of monocytes defined as 
CD11bhi F4/80-Ly6Chi and their expression of CX3CR1 and CCR2 receptors represented as median 
fluorescence intensity.  
 
2.2 Analysis of therapeutic soluble factors in the plasma  
To check whether intravenous delivery of infected bone marrow cells elevated the 
amount of therapeutic factors in the plasma, we collected blood samples 24 hours after each 
injection, as well ~1 week before surgery (baseline) and at 28 days post-I/R (experimental 
endpoint). 
Analysis of the presence of S1P in the plasma was performed 24h after injection of 
LV_SphK1 BM (day 8 post-MI), at the baseline and endpoint. We observed an increased 
amount of S1P in the treated group at day 8 post-MI (24h after BM_hSphK1 injection) 
although not significant (Figure 16). Interestingly, at 28 hours after myocardial infarction, 
the amount of S1P in treated group returns to baseline levels, whereas in the control group, 
it is noticeably increased. 
The hVEGF was not detectable in the plasma of the tested mice (data not shown). 
Results 
68 
 
 
Figure 16. S1P levels in the plasma of mice injected with bone marrow cells overexpressing 
hSphK1 and controls. S1P presence was measured before I/R (t_0), 24h post LV_SphK1_BM 
injection (t_8) and at endpoint (t_28). One-way ANOVA, n=3, 4 mice in control and therapeutic 
groups respectively in one experiment.    
 
2.3 Visualization of intravenously injected bone marrow 
cells homing to the damaged heart 
To confirm the ability of intravenously injected bone marrow cells to migrate to the 
infarcted myocardium, we used bone marrow cells from Gt(ROSA)26Sortm4(ACTB-tdTomato,-
EGFP)Luo mice, which express dtTomato red fluorescence protein (RFP) on the membrane of 
all cells/tissues. 5x106 red bone marrow cells or PBS were intravenously injected at day 4 
after ischemia-reperfusion and hearts were analyzed 24h after injection.  
Histological analysis of the infarct zone of the hearts stained with anti-RFP antibody, 
confirmed the presence of cells with membrane dtTomato in the granulated tissue of the 
hearts of mice injected with red bone marrow cells (Figure 17A, lower panel) and also in 
the epicardium (Figure 17A, upper panel), although less.  In contrast, in PBS injected mice, 
red fluorescence signal was not detected at the cell membrane. We observed unspecific red 
signal which followed the pattern of autofluorescence-control green channel. Infarct zone of 
the heart, similarly to other injured tissues, is characterized by a high level of 
autofluorescence in green but also in red channel of confocal microscopy, coming from 
infiltrating phagocytic cells (Figure 17B). 
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2.4 Analysis of the combined VEGF/S1P therapy on the left 
ventricle contractile function 
To assess the systolic function of the left ventricle, echocardiographs were performed 3 
days after surgery (one day before beginning the treatment) and at the endpoint, 28 days 
post-I/R. The LVEF and stroke volume (SV) were measured to assess contractile function 
 
Figure 17. Intravenously injected bone marrow cells home to the infarcted myocardium. At 
day 4 after myocardial infarction, mice were intravenously injected with 5x106 dtTomato bone 
marrow cells or PBS. 24h after injection mice were sacrificed and stained with anti-RFP-594 
antibody. A. In the infarct zone of mice injected with dtTomato_BM, we observed dtTomato+ cells 
(arrowheads), which were not present in the green channel (autofluorescence control). Upper panel 
shows cells infiltrating into epicardium. Lower panel shows cells infiltrating the granulated tissue. 
B. Unspecific red fluorescence signal in the heart of PBS-injected mice present the same pattern 
as green autofluorescence channel. Scale bar 50µm.  
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of the hearts. The LVEF describes the percentage of blood volume pumped and the SV is 
the actual volume of blood pumped by the heart during each contraction.  
As expected, LVEF and SV decreased 3 days post-I/R compared to healthy mice (Figure 
18A, C). At 28 days post-I/R, LVEF remained low, with no differences between groups 
(Figure 18A). In the analysis of individual mice, the treated group showed a slight increase 
in LVEF, although not significant (Figure 18B). At 28 days post-I/R, SV recovered in both 
groups, although to a higher extent in the mice treated with the combined angiotherapy 
(Figure 18C, D). 
 
Figure 18. Systolic function of hearts from control and VEGF/S1P treated mice. 
Echocardiography was performed at day 3 post-I/R and mice were divided into control and treated 
groups. End-point echocardiography was performed at day 28 post-I/R. A. Left ventricle ejection 
fraction (LVEF) of treated, control and healthy mice. B. LVEF of individual mice from control 
and treated group. C. Stroke volume (SV) of treated, control and healthy mice. B. SV of individual 
mice from control and treated group.  One way ANOVA(a, c) and paired t-test (b, d), n=12 control, 
18 therapy, 3 independent experiments.  
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2.5 Impact of VEGF/S1P gene-cell therapy on cardiac 
remodeling 
As described in the Introduction, a consequence of insufficient repair after myocardial 
infarction is adverse cardiac remodeling, which eventually leads to heart failure. One of the 
symptoms of heart failure is dilation of the heart muscle, manifested by an increase of left 
ventricle volume, especially in diastole, a change in the heart geometry towards a more 
circular shape, and at a cellular level by cardiomyocyte hypertrophy. Therefore, we 
examined whether combined BM_hVEGF + BM_SphK1 angiotherapy had an impact on 
heart remodeling.   
2.5.1 Analysis of cardiac dilatation 
Over time after MI the heart dilates as a result of pathological remodeling. Therefore, 
left ventricle end systolic and diastolic volumes (LVESV, LVEDV) were measured in 
control and treated hearts. As expected, at day 3 post-I/R, we observed no changes in both 
parameters between healthy and infarcted mice (Figure 19, C).  
 
 
Figure 19. Analysis of left ventricle dilatation using echocardiography. Echocardiography was 
performed at day 3 (before the therapy started) and 28 (at the endpoint) post I/R. Left ventricle 
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end systolic volume (LVESV) and left ventricle diastolic volume (LVEDV) were measured in 
hearts from VEGF/S1P treated and control mice after MI and in healthy mice (A,C respectively). 
LVESV and LVEDV of individual mice of PBS and BM_hVEGF/BM_hSphK1 treated mice (B,D 
respectively). One way ANOVA(a, c) and paired t-test (b, d), n=12 control, 18 therapy, 3 
independent experiments. 
 
At day 28 post-I/R, LVESV and LVEDV increased significantly when compared to 
healthy hearts, although to a lower extent in the mice treated with BM_hVEGF + 
BM_SphK1. Analysis of left ventricle volumes in individual mice after MI, showed no 
differences between groups (Figure 19B, D). 
The observed changes in left ventricle systolic and diastolic volumes, although mild, 
suggested ameliorated remodeling of the hearts in the treated group. Therefore, we decided 
to check global geometry of the hearts from VEGF/S1P-treated and control mice.  Despite 
no changes in the heart weight (Figure 20A), we observed that hearts from the treated group 
kept their ellipsoid-like shape, whereas controls became rounder (Figure 20C).  
 
 
Figure 20. BM_hVEGF/BM_hSphK1 combined therapy prevented changes in the geometry 
of the heart after MI. A. Heart to body weight ratio. B. Representative images of dissected hearts 
from control and treated mice. C. Roundness of the heart was measured using ImageJ software. A. 
One way ANOVA, n=5,7,12 (no I/R, control and therapy accordingly). C. Unpaired t-test, n=11,16 
(control, treated). Two independent experiments. 
 
2.5.2 Cardiomyocyte hypertrophy  
In order to determine changes in cardiomyocyte size, which is an important indicator of 
cardiac remodeling, we performed histological analysis of the heart tissue using anti-laminin 
antibody (Figure 21A). Analysis was performed in the remote zone of the heart due to the 
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fact that most of the dead cardiomyocytes in the infarct zone at this point are replaced by 
scar tissue.  
Quantification of cardiomyocyte morphology, showed a decreased area and perimeter of 
cardiomyocytes in hearts from BM_hVEGF/BM_hSphK1-treated compared to control mice 
(Figure 21B, C). This suggests that PBS-treated mice developed cardiomyocyte 
hypertrophy whereas combined proangiogenic treatment had better preservation of 
cardiomyocyte size.   
 
 
Figure 21. Gene-cell BM_hVEGF/BM_hSphK1 therapy prevents cardiomyocyte 
hypertrophy after MI. Hearts from PBS and BM_hVEGF/BM_hSphK1-treated mice were 
stained using anti-laminin antibody. A. Representative images of cardiomyocytes from remote 
zone of control and treated hearts. Maximal projection, scale bar 50µm. Cardiomyocyte area (B) 
and perimeter (C) was measured using ImageJ software. Unpaired t-test, n=11,16 (control, 
therapy) in two independent experiments.  
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2.6 Analysis of myocardial infarct size 
Initial infarct size caused by the loss of viable myocardium, as well as its later expansion, 
plays an important role in cardiac remodeling and prognosis86.  To quantify the infarct size, 
series of seven cuts from the apex to the base of hearts were stained using Masson-Trichrome 
(Figure 22A). Area occupied by scar was selected using ImageJ software and compared with 
total left ventricle area.  
 
 
Figure 22. Infarct size and extension in hearts from VEGF/S1P- and PBS-treated mice. 
45min ischemia/reperfusion model of myocardial infarction was performed and infarct size was 
analyzed 28 days after, in serial heart cuts stained with Masson-Trichrome. Infarct size is 
represented as % of left ventricle area occupied by scar tissue. A. Representative image of the 
staining and quantification of each heart as an average of serial cuts (B). C. Analysis of serial cuts 
from apex to the base of the heart and comparison of infarct size on each level. D. Infarct size of 
the cuts closest to the base of the heart. Unpaired t-test, two-way ANOVA (levels comparison), 
n=11 control, n=16 therapy in two independent experiments. 
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When we looked at the average of all cuts, the percentage of area occupied by the 
scar between groups show no differences (Figure 22B). Then, we analyzed whether there 
were differences in the scar expansion/extension when compared to correlative cuts (from 
apex to the base). Indeed, except in the section closest to the cardiac apex (cut 1), we 
observed a slight but consistent decrease in the area occupied by fibrotic tissue in the treated 
group, that reached significance in the section closest to the base of the heart (cut 7) (Figures 
22C and 22I). Taking into account the fact that in the permanent LAD coronary artery 
occlusion model, MI appears largely in the area of the heart closest to the apex87. These 
results suggest that expansion of the fibrosis is diminished in the treated group. 
 
2.7 Influence of VEGF/S1P gene-cell therapy on the 
inflammatory response after MI 
As mentioned in the introduction, prolonged inflammatory response is one of the main 
players in the pathology of myocardial infarction. Therefore, we decided to analyze the 
monocyte subsets in the blood and the cardiac macrophage content of BM-hVEGF/BM-
SphK1 and PBS-treated mice.  
 
2.7.1 Analysis of peripheral blood monocytes  
We sought to compare the phenotype of peripheral blood monocytes at three time points: 
before I/R (healthy mice), 14 days post I/R (one week after last injection), and 28 days post-
surgery (at the experimental endpoint).   
Circulating monocytes are usually defined by the expression of the following cell surface 
markers: CD45+ CD115+ CD11b+ and are then divided into Ly6Chi and Ly6Clow 
subpopulations. However, we were interested in analyzing two monocyte subsets which take 
part in the immune response upon myocardial infarction: proinflammatory Ly6Chi CX3CR
low 
CCR2+ and patrolling Ly6C
low CX3CR
hi CCR2- with inflammatory-attenuating 
properties14,88,89. As CX3CR1 receptor is expressed on monocytes but not on neutrophils, we 
were able to distinguish the monocyte subset despite not using a CD115 marker90. We 
defined monocytes as CD11b+ CX3CR1
+ population and furthermore, Ly6Chi and Ly6Clow 
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subpopulations (Figure 23A). Consistently with the definition of proinflammatory 
monocytes, the Ly6Chi subset expressed lower levels of CX3CR1 and higher CCR2 than 
Ly6Clow patrolling monocytes which express CX3CR1hi and CCR2low (Figure 23B). 
 
 
Analysis of total peripheral blood monocytes, showed a decrease in control group 28 
days post-I/R comparing to the healthy animals (Figure 24A). More detailed analysis 
revealed significantly lower amount of Ly6Clow monocytes in PBS-treated group at 14 days 
post-I/R when compared to healthy animals (Figure 24C). Ly6Clow monocytes also 
 
Figure 23. Monocyte gating strategy. Peripheral blood samples were harvested before I/R, at 
day 14 and 28 post I/R, and analyzed using flow cytometry. A. Monocytes were defined as CD11b+  
CX3CR1+ population and further defined as  Ly6Chi and Ly6Clow. B. Expression of CX3CR1 and 
CCR2 receptors on Ly6Chi and Ly6Clow monocyte subpopulations at the middle and end-point after 
myocardial infarction.   
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decreased in the BM_hVEGF/BM_SphK1 group, but to a lower extent. However, over time, 
the amount of Ly6Clow monocytes increased in the post-I/R mice and at 28 days there were 
no differences compared to the healthy animals. Notably, in addition to the significantly 
lower percentage of the Ly6Clow population found in the blood of PBS-treated group 14 days 
post-I/R, the expression of CX3CR1 was significantly lower and of CCR2 higher compared 
to the healthy animals. Therefore, not only this population was lowered in number, but also 
lost its typical phenotype described as inflammation-attenuating: LyC6low CX3CR1
hi 
CCR2low (Figure 24E).  
 
 
Figure 24. Distinct impact on blood monocytes in response to cardiac damage over time 
between PBS and BM_hVEGF/BM_hSphK1-treted mice. Blood samples were harvested 
before I/R, at day 14 and 28 post-I/R, and analyzed using flow cytometry. A. Monocytes defined 
as CD11b+  CX3CR1+ and represented as % of live cells. B.  Ly6Chi and C. Ly6Clow monocyte 
subpopulations represented as % of monocyte population. Expression of CX3CR1 and CCR2 
receptors on D. Ly6Chi and E. Ly6Clow monocyte subpopulations represented as median 
fluorescence intensity. One way ANOVA, n=6 in no I/R control, n=3 mice (14d, both control and 
therapy), n=6 (d28 control), n=11 (d28 therapy) in one experiment. 
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Despite no changes in the percentage of the Ly6Chi subpopulation between groups 
and time-points, we observed increased expression of CX3CR1 receptor in control group 14 
days post-I/R. Additionally, CCR2 expression increased in the control group at both 14 and 
28 days after I/R compared to the healthy animals (Figure 24D,E).   
Based on the fact that some of the peripheral blood monocytes mobilized in response 
to MI come from the splenic reservoir15, we decided to analyze monocyte and macrophage 
content in the spleen at the experimental endpoint (28 days post-I/R). To analyze splenic 
monocyte subsets we used the same gating strategy as for the peripheral blood (Figure 23). 
We did not observe differences in total monocyte amount, but a decreased amount of the 
Ly6Clow subset in control and treated animals when compared to the no-I/R group (Figure 
25B, C). Among the Ly6Chi monocyte subset, there were no differences between analyzed 
groups, but there was a trend towards an increase within infarcted versus healthy animals.   
 
  
 
Figure 25. Characterization of splenic monocyte/macrophage population at 28 days post-I/R 
in VEGF/S1P- and -PBS treated mice. Spleens of control, treated and healthy mice were 
harvested and analyzed using flow cytometry. A. Macrophages were defined as CD11bhi F4/80+, 
Monocytes as CD11b+  CX3CR1 (B), and represented as % of live cells. C. Monocyte Ly6Chi and 
Ly6Clow subpopulations. One way ANOVA, n=6 no I/R, n=3 (control and therapy) in one 
experiment. 
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Despite a very low percentage of macrophages, we observed an increase in mice 
which have undergone a myocardial infarction, to a higher extent in the VEGF/S1P-treated 
group (Figure 25A).  
 
2.7.2 Impact of VEGF/S1P gene-cell therapy on cardiac macrophages 
after I/R 
In addition to analyzing changes in the inflammatory response on the systemic level, we 
next  checked whether there were differences in the macrophage content in the hearts of 
control and treated mice at the experimental end point.  
The hearts were stained with an anti-F4/80 antibody using the immunohistochemistry 
method and the percentage of F4/80+ nuclei in the infarcted and remote zone of the hearts 
was quantified (Figure 26).  
 
 
Figure 26. Immunohistochemical analysis of macrophage content in hVEGF/S1P-treated 
and control hearts. At 28 days post I/R hearts were stained using F4/80 pan-macrophage marker 
and analysis of remote and infarct zone was performed. A. Representative images of macrophages 
in the infarct and remote zone B. Macrophages were defined as F4/80+ cells and represented as % 
of total number of cells. Scale bar 50µm. Unpaired t-test,  n=13 therapy and n=10 control, in two 
independent experiments.  
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As shown in Figure 26B, F4/80+ macrophages in the infarct zone were representing 
over 15% of the cells in both groups and about 4% in the remote zone.  In the infarct zone, 
we observed no significant differences in macrophage content between control and treated 
group. However, in the remote zone of hVEGF/S1P-treated group, the percentage of cardiac 
macrophages was slightly lower compared to the control group. Additionally, the 
distribution between subjects within treated group was more consistent than in control.  
In addition to immunohistochemistry, we performed immunofluorescence staining 
using an anti-CD68 antibody to validate the data from F4/80 staining (Figure 27). We 
observed that the percentage of CD68+ macrophages in the remote zone was slightly higher 
compared to F4/80 staining (~6% and ~4% respectively). Similarly to F4/80+, the percentage 
of CD68+ macrophages in the remote zone of hVEGF/S1P-treated group was lower, yet still 
not significant (Figure 27). Moreover, the distribution of subjects within the 
BMhVEGF/BMhSphK1-treated group was more consistent, and resembled the one observed in 
the F4/80 staining. 
 
 
Figure 27. Immunofluorescence analysis of macrophage content in the remote zone of hearts 
from PBS and VEGF/S1P-treated mice. Staining with anti CD68 macrophage  marker was 
performed in the remote zone of hearts 28 post-I/R. Representative images of CD68+ cells (left) 
and quantification of percentage of macrophages within total number of cells. Scale bar 25µm. 
Unpaired t-test, n=15 therapy, n=9 control, in two independent experiments. 
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2.8 Effects of VEGF/S1P gene-cell therapy on cardiac 
microvasculature after I/R 
The primary goal of our designed angiotherapy was to increase and modulate 
endogenous angiogenesis after I/R, by sequential delivery of VEGF and S1P using lentiviral-
infected bone marrow cells as a vehicle.  
Histological analysis of 15um-thick heart sections was performed to observe changes in 
the microvascular response to the applied therapy after I/R. We decided to perform 
immunostaining on thicker than standard sections to achieve semi-3D images of the 
vasculature network. Heart sections of control and treated hearts were stained with anti-
CD31 antibody for endothelial cells, anti-SMA for smooth muscle cells covering arterioles, 
and anti-PDGFRβ for mural cells and myofibroblasts (Figure 28). Confocal images were 
analyzed by a MATLAB-based automated method developed in our lab70. This image 
analysis method allowed us to compare the microvasculature of the PBS and VEGF/S1P-
treated hearts at the structural and segment levels.  
Structural analysis using Minkowski functionals and fractal-based analysis allowed us to 
observe the vasculature as a whole network. Minkowski functionals describe the morphology 
of a given structure, in this case, vascular volume densities of a distinct microvascular 
network category (Figure 29A).  In the case of the infarct zone vasculature, we observed 
increased capillary volume density in hearts from VEGF/S1P-treated mice with no 
differences in total vascular volume density. At the same time, the vascular volume density 
of large vessels increased in hearts of PBS-treated mice. This observation indicates an 
angioadaptation mechanism is occurring in response to capillary loss, impaired oxygenation, 
and flow redistribution in the remaining vessels70,91. In the remote zone, total vascular 
volume density also remained unchanged between groups. Moreover, similarly to the infarct 
zone, we observed a trend towards an increase in capillary volume density in hearts from 
treated mice, and an increase in volume density of large and medium-size vessels in hearts 
from the PBS-treated group. An analysis of fractal parameters allowed us to observe 
differences in the complexity of the network structure (fractal dimension), heterogeneity in 
the distribution of gap sizes (lacunarity), and capacity of the blood to flow through the 
structure (succolarity) (Figure 29B).  
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Figure 28. Representative images of the myocardial vasculature from infarct and remote 
zones of hearts from VEGF/S1P-treated and control mice. Transverse sections of mouse hearts 
(approximately 15µm-thick to obtain semi-3D vasculature network) were stained for endothelial 
cells with anti-CD31 antibody, smooth muscle cells with anti-SMA, and mural cells and 
myofibroblasts with anti-PDGFRβ. Images of the vasculature in infarct (A) and remote (B) zone 
of treated and control hearts. Scale bar: 50µm. 
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In addition, we observed a more homogenous distribution of non-vascularized areas in 
the hearts from treated animals, which is represented as a strong trend towards lower 
lacunarity in both remote and infarct zone. 
 
Figure 29. Structural analysis of the whole vasculature shows increased capillary content in 
the infarct zone of hearts from hVEGF/S1P-treated mice. A. Morphology of the vasculature 
assessed using Minkowski functionals. Vascular Volume Density consist; Arteriole Volume 
Density (defined as density of CD31+ vessels covered with smooth muscle cells), Capillary 
Volume Density (defined as density of CD31+ vessels of diameter <5µm), Medium-size Vessels 
Volume Density (defined as density of CD31+ vessels of diameter 5.1 to 8.7µm) and Large Vessels 
Voluvme Density (defined as density of CD31+ vessels of diameter >8.7µm). B. Fractal-based 
analysis of vasculature network. Fractal Dimension metrics describe morphological complexity 
of the network, Lacunarity describe heterogeneity of gap sizes and Succolarity shows capacity of 
a fluid to flow through the network.  n= in two independent experiments, non-parametric t-test. 
 
Detailed comparison of individual vessels in hearts from treated and control mice was 
possible using 3D graph-based segment level analysis. Consistent with the analysis of 
capillary volume, we observed a higher percentage of capillary content in the hearts from 
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VEGF/S1P-treated mice, although not significant in the case of the infarct zone. 
Additionally, in the remote zone of control hearts, the percentage of medium-sized and larger 
vessels was higher (Figure 30D). 
 
 
Figure 30. Applied proangiogenic therapy increases capillary content in remote zone and 
improves oxygenation of treated hearts. Analysis of the vasculature performed using graph-
based method. A. Maximal extravascular distance measured in µm. B. Damage index defined as 
percentage of PDGFRβ+ volume not associated with vessels (i.e. myofibroblasts). C. Number of 
endothelial cells per mm3 of vascular volume. D. Percentage of capillaries (left), medium-sized 
vessels (middle) and large vessels (right) in infarct and remote zone vasculature of treated and 
control hearts.  n= 9 in control, n=12 treated in two independent experiments (total 192 images 
analyzed), non-parametric t-test. 
 
Moreover, oxygen diffusion defined as smaller maximal extravascular distance, was 
improved in the VEGF/S1P-treated mice compared to the controls in both the infarct and 
remote zones (Figure 30A). This result was expected in light of the observed increase in 
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capillary volume and a higher percentage representation in the hearts from treated mice. 
Additionally, the amount of endothelial cells per vascular volume was also higher in the 
infarct zone of the hearts from the treated group, as well as in the remote zone although not 
significantly (Figure 30C). It might be a consequence of delivering hVEGF, which enhanced 
endothelial cell proliferation.  
Notably, this 3D image analysis allowed for the quantification of myofibroblasts, defined 
as PDGFRβ+ cells distant from the vessels, as it was described that myofibroblasts from 
various tissues express PDGFRβ92,93. Damage index showed an increased amount of 
myofibroblasts in the infarct zone of the control hearts compared to the treated hearts (Figure 
30B). In the case of remote zones, as expected, the damage index was close to zero, 
indicating the absence of myofibroblasts in this area of the hearts. 
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3. Analysis of angiogenesis-related events in 
porcine myocardium after ischemia-reperfusion 
injury  
As a member of the CardioNext ITN network, I was involved in performing experiments 
on pigs to evaluate changes in the heart microvasculature after ischemia-reperfusion injury 
using confocal-based imaging method. 
To analyze cardiac microvasculature after myocardial infarction, we used hearts of pigs 
which had undergone 30-minute occlusion of LAD artery followed by 1, 3 and 7 days of 
reperfusion. Basal hearts of the same age pigs served as controls.  
 
Figure 31. Representative images of the pig heart vasculature stained with various vascular 
markers. An IB4, CD31 and Ve-Cadhering staining of the infarct and remote zones of pig hearts 
at 45 days post I/R.  In addition to EC, IB4 stains infiltrating cells in the remote zone (indicated 
by arrowheads). CD31 and VE-Cadherin specific vascular junction pattern in both remote and 
infarct zones. Maximal projection of 100µm-thick porcine heart tissue fixed with 0.4% PFA. Scale 
bar 50um.  
 
To stain the microvasculature, we started by testing the reactivity of available antibodies 
in the pig tissue. We tested Isolectin B4, CD31 and VE-Cadherin. Isolectin B4 staining was 
vessel specific in the remote zone; however, in the infarct zone where the inflammation 
process occurs we observed a large contamination of the macrophage staining. Therefore, an 
IB4 staining was excluded from the study (Figure 31, arrowheads). We also tested a CD31 
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marker, which is present in endothelial cell junctions as well as in other cell types such as 
platelets, monocytes and macrophages94. In our settings, the CD31 staining was EC specific, 
even in the infarcted zone, and we could observe CD31+ infiltrating cells only when 4%PFA 
fixation was used (personal observation).  
 
 
Figure 32. Representative images of microvasculature staining of porcine myocardium at 1, 
3 and 7 days post I/R and basal.  Immunostaining of VE-Cadherin for endothelial cells and SMA 
for smooth muscle cells/pericytes in the remote and the infarct zone. Maximal projection of 
approximately 70µm-thick sections, scale bar 50µm.   
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Furthermore, we tested the VE-Cadherin antibody, which is an exclusive endothelial cell 
junction marker95, and as expected, it showed a similar staining pattern as CD31.  Ultimately, 
we decided to use VE-Cadherin due to host species compatibly with other markers used for 
immunostaining.  
 
Figure 33. Quantification of vasculature changes in infarct and remote zones of porcine heart 
over time after I/R. Pig hearts after 30min of ischemia followed by 1, 3 and 7 days of reperfusion 
were analyzed. Tissue from remote and infarct zone was cut with ~100µm thickness, stained with 
VE-Cadherin and SMA, and 3D confocal images of were analyzed using automated method. A. 
Capillary density calculated as a number of capillaries per mm2 in remote and infarct zone overtime 
post-I/R. B. Percentage of large vessels (defined as vessels with diameter >8.2µm). C. Maximal 
extravascular distance at different time-points after I/R. Our data published in70. 
 
To address changes in the microvasculature network and its functionality, hearts were 
stained with VE-Caherin and α-SMA (Figure 32). To perform detailed analysis of the 
vasculature, a 3D-automated image analysis pipeline was developed in our lab for confocal 
images70. The obtained results showed that in the infarct zone, capillary density decreased 
gradually from over 1200 capillaries per mm2 at 1 day after I/R to around 400 
capillaries/mm2 at day 7, whereas in the remote zone it remained stable (Figure 33A). At 
the same time, a percentage of large vessels in the infarct zone (with diameter bigger than 
8.2µm, e.g. venues and arterioles) increased from 5% at day 1 to 7.6% at day 7 post-I/R 
(Figure 33B). This data indicate loss of capillaries most probably due to the impaired oxygen 
and nutrient supply caused by ischemia, and also an adaptation mechanism through 
vasodilation to compensate for an impaired microvascular network. This is supported by the 
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increasing maximal extravascular distance within infarct zone vasculature overtime (Figure 
33C).  
Data obtained from infarct zone vasculature analysis indicate gradual regression of 
vascular network in the ischemic heart with significant differences between capillary density 
and SMA coverage as early as between day 3 and 7 post MI. Thus, our results obtained in 
pig tissue suggest that the time window for the therapies impairing vasculature loss – that is, 
pro-angiogenic – should be considered to be started around day 3 post-I/R 
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Over the past decades, the need for an effective therapy to improve or rather to prevent 
adverse remodeling and as a consequence a failure of the heart after myocardial infarction 
remains unmet. Since introduction of angioplasty in the late ‘70s, acute treatment of 
myocardial infarction has improved dramatically, although the mortality rate caused by CVD 
remains high96. Trying to overcome the inability of adult cardiac muscle to regenerate, many 
therapies have been implemented, including cell therapies, gene therapies (also with the use 
of viral vectors), the delivery of numerous cytokines, and soluble factors. These therapies 
aimed at various goals, including the prevention of cardiomyocyte death, the reprograming 
of cardiac fibroblasts into cardiomyocytes or cardiac progenitors, and modulating 
angiogenesis52-55,60,97,98. In recent years, more importance has been given to modulating 
immune response after myocardial infarction and its beneficial effects on heart 
regeneration14,16,99,100.  
After many years of research, including clinical trials, there is still room for 
improvement. In the field of proangiogenic therapies, use of a strong proangiogenic factor, 
VEGF, has brought a modest improvement. One of the main limitations of these studies 
seems to be a delivery route of healing factors, from delivery of the recombinant protein101,102 
and gene delivery using plasmids52,53 or modified RNA103 to virus-based approaches, mostly 
using AAV57,59,60. On the other hand, cell therapies whose main effect is believed to be based 
on secreting factors show some improvement in vascularization, but it is not sufficient104,105. 
Therefore, our hypothesis was that combining these two approaches (delivering 
beneficial cells but additionally transducing them to overexpress proangiogenic factors) 
might bring an improvement in heart performance after myocardial infarction. To modify 
the cells, we used lentiviral vectors because of their ability to transduce all cell types with 
high effectiveness. Because we used a general SFFV promoter, we decided to infect the cells 
ex vivo and inject them into the recipient mice afterwards. By using this approach, we were 
able to overcome safety concerns related to the lentivirus’s potential to cause insertional 
oncogenesis.  
After myocardial infarction, angiogenesis is one of the endogenous healing processes 
taking part after the acute inflammation response. We believed that sequential delivery of 
bone marrow cells, lentivirally-transduced to overexpress VEGF and other proangiogenic 
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factor, would help to mimic and boost endogenous angiogenesis, and to overcome the 
limitations appearing while using only gene/cell therapy and single angiogenic-related 
factors.  
Prior to the mouse study, in vitro screenings of various combinations of proangiogenic 
factors were performed using an aortic ring assay. A broader screening was performed using 
commercially available hVEGF, hAng1 and S1P. Combinations of these factors have been 
used before to promote angiogenesis81,82,106,107, although to the best of our knowledge they 
have not been compared simultaneously. To determine if a single or sequential approach is 
more effective at inducing sprouting, we treated rings with single factors as well as with 
hVEGF followed by hAng1 or S1P. We also tested how prolonged exposure to hVEGF 
influences the sprouts, because it has been observed before that long-term exposure to VEGF 
is deleterious to newly-formed vessels61. To check this, after adding hAng or S1P, we 
continued introducing hVEGF until the end of the experiment. We found that S1P alone is 
able to increase sprouting significantly. Additionally, we observed that combinations of 
either sequential or prolonged treatment with VEGF and S1P is more effective at inducing 
sprouting than any combination of VEGF and Ang1. Sequential delivery of VEGF followed 
by S1P in matrigel assays has shown greater EC recruitment and a higher maturation index 
(the percentage of vessels co-localized with αSMA+ cells) compared to single or reverse 
order delivery of these factors82. In our experimental setting, VEGF/S1P sequential delivery 
also remarkably induced sprouting, although contrary to the matrigel study, we observed 
similar improvement in sprouting when using S1P alone. In the matrigel study, plugs were 
implanted in vivo into the dorsal skin; therefore, the angiogenic response was exposed to an 
environment with more complex variables than in an aortic ring setting. These factors might 
have limited the effect of single S1P exposure that we observed in aortic rings.  
An analysis of smooth muscle cell coverage of new sprouts showed no differences 
between groups, except a decrease in the group with prolonged delivery of hVEGF in 
combination with S1P. It has been described that stimulation of endothelial cells with VEGF 
causes overexpression of S1P1 receptors on these cells; and in isolated arteries, enhances 
S1P-mediated vasorelaxation and eNOS phosphorylation33. This effect, at first favorable and 
contributing to prosurvival and a proangiogenic program of capillary endothelium, might 
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cause disruption in mural cell coverage when excessive due to the continuous presence of 
VEGF.  
In the next step, aortic rings were cultured in the presence of msBM cells overexpressing 
selected factors, to check whether exposure to cell-derived factors would be able to 
reproduce the phenotype observed before. This step was crucial since we planned to use bone 
marrow cells as a vehicle to deliver proangiogenic factors after myocardial infarction. We 
observed the highest abundance of sprouts in rings treated with a combination of BMhVEGF 
followed by BMhSphK1. On the other hand, SMA coverage in this group was decreased, 
although it remained higher than 50%. Despite washing away BMhVEGF while adding 
BMhSphK1, some of the cells could have migrated into the collagen matrix and kept secreting 
hVEGF in addition to S1P from BMhSphK1. This was similar to the lowest SMC coverage in 
the group with prolonged hVEGF exposure in combination with S1P observed in the first in 
vitro approach. Treatment with wild type bone marrow cells did not increase sprouting of 
aortic rings, and therefore they were not used in further studies.  
We concluded that the combination of BMhVEGF followed by BMhSphK1 induced sprouting 
most efficiently; therefore, despite lowered SMC coverage, this approach was used to treat 
mice with the I/R model of MI. We decided to use a combination of factors, even though in 
the soluble factor approach, the use of S1P alone significantly induced sprouting as well. We 
hypothesized that the cross-talk between VEGF and S1P discussed above may have a 
favorable effect in vitro as observed in the aforementioned matrigel study. 
The best time window during which to start the treatment after MI remained an open 
question. A 3D analysis of changes in porcine heart microvasculature performed in our lab 
revealed a possible time window for therapeutic intervention to be the 3rd day after MI. At 
this time, the structure of the vasculature is mostly preserved, but its function becomes 
impaired, manifested in larger extravascular distances causing disturbed oxygen diffusion70. 
Additionally, the endogenous angiogenesis after the acute inflammatory phase of MI is 
believed to appear from 3 to 14 days after the ischemic event3,89,108.  
We decided to use the 45-minute ischemia/reperfusion model of MI rather than 
permanent LAD ligation to mimic the clinically-common model of MI, which includes PCI 
intervention. Following the aortic rings experimental set-up, BMhVEGF were intravenously 
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injected (4 days post I/R), followed by BMhSphK1 at day 7. Experiment with dtTomato bone 
marrow cells, intravenously injected 4 days post-I/R, confirmed that these cells are capable 
of homing in on ischemic myocardium and are present there 24 hours after injection. On the 
other hand, human VEGF in the mice plasma 24 hours after cell injection was not detectable 
using ELISA. That might have been due to the very short half-life of this protein in the 
plasma, which is only a few minutes109. The presence of S1P in the plasma 24 hours after 
BMSphK1 injection was increased, although not significantly. The limitation here was the 
small number of animals tested (n=3). 
An analysis of bone marrow cells before injection into infarcted mice showed that over 
50% of them were monocytes. These cells were cultured and transduced in the presence of 
SCF and M-CSF; therefore, we expected a shift towards a myeloid lineage. We observed a 
higher monocyte expression of CX3CR1 receptors on cells infected with the lentivirus 
compared to the wild-type bone marrow. Interestingly, bone marrow cells infected with 
LV_hSphK1 expressed a higher amount of this receptor than ones infected with LV_hVEGF. 
A higher expression of this receptor may facilitate the homing of these cells on to infarcted 
myocardium, especially in the case of BMhSphK1 which were injected at the later time point. 
Time-lapse imaging of immune cells homing on to infarcted myocardium has demonstrated 
increasing infiltration of CX3CR1
+ monocytes into the injury site up to day 6 post-MI, which 
was the experimental endpoint110. Furthermore, the role of CX3CR1 in the process of cell 
homing into the injury site was described in a rat model of cerebral artery occlusion, where 
silencing of CX3CR1 expression in MSC notably decreased their homing into injured brain 
after intravenous injection111. Moreover, we observed lower amounts of macrophages in 
cells infected with lentivirus, which may have a beneficial effect since already differentiated 
macrophages are not capable of extravasating into the damaged tissue.   
In terms of the global heart function, VEGF/S1P therapy resulted in better recovery of 
the stroke volume 28 days after I/R despite no differences in ejection fraction between 
groups. Additionally, adverse cardiac remodeling seemed to be ameliorated in the treated 
animals as seen in the reduced increase of LVESV and LVEDV compared to controls at 28 
days post I/R. This finding was supported by an analysis of the whole organ shape and the 
observation that treated hearts kept their ellipsoid-like shape, whereas controls become more 
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round, suggesting heart dilation. Furthermore, when we analyzed cardiomyocytes in the 
remote zone, we observed cardiomyocyte hypertrophy in the hearts of the control animals. 
It has been shown that in a permanent LAD ligation model of MI, cardiomyocyte 
hypertrophy starts at 1 week post-MI, and continues to increase concurrently with the left 
ventricle dimension starting at 2 weeks post-MI112. In the I/R model used in our study, which 
is less severe than LAD ligation, it seemed that the development of pathological changes 
may have started later.  Furthermore, although at 4 weeks after MI we clearly saw 
cardiomyocyte hypertrophy in the non-treated group and a change in the whole heart shape, 
we did not observe dilation of the left ventricle in echocardiography.  
BMhVEGF/BMhSphK1 angiotherapy had no influence on overall cardiac fibrosis, although 
it seemed to prevent scar extension. When we analyzed the part of the heart most distant 
from the injury site, we observed significantly less fibrosis in the treated group. This might 
have been due to the fact that the control hearts, which showed signs of cardiac dilation, 
started developing secondary fibrosis. The damage index, defined as the amount of 
myofibroblasts present in the tissue, was significantly lower in the infarct zone of treated 
hearts. This observation correlates with a constant, although not significant, decrease in 
fibrotic content measured using Masson-Trichrome staining on various levels of the left 
ventricle. 
As mentioned before, more attention has been given to the analysis of the immune 
response after MI because of its importance in the recovery process and prognosis113-115. In 
addition to its role in angiogenesis, S1P is also involved in immune response, especially 
immune cell trafficking116. Therefore, we decided to analyze the immune response of treated 
and control animals. In the blood of control mice, 14 days after I/R we observed a larger 
decrease in Ly6Clow monocytes compared to the healthy mice. This fact might have had an 
influence on the healing process, especially since this monocyte subset plays an important 
role in healing after MI14,89. Additionally, the chemokine receptor profile of these cells was 
altered. We observed a lower expression of CX3CR1 and a higher expression of CCR2 in 
this subpopulation, which may suggest a loss of the ‘reparative’ phenotype of these 
monocytes. It has been demonstrated that depletion of the CCR2 receptor is beneficial for 
preventing cardiac remodeling in a mouse model of MI117,118. Moreover, better preserved 
expression of the CX3CR1 receptor on circulating Ly6C
low monocytes in mice treated with 
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BMhVEGF/BMhSphK1 could have a positive effect on their recruitment and the promotion of 
angiogenesis in the injury site as has been described in hind limb ischemia119 and carotid 
injury120 models.  
In addition to analyzing the systemic inflammatory response, we examined cardiac 
macrophage content, as it is related to the healing of infarcted myocardium16. We observed 
a higher amount of macrophages in the remote zone of control hearts confirmed by two 
experimental methods, yet it was not significant. This increase might have been a result of 
greater infiltration or proliferation. It has been described that cardiac macrophages 
proliferate in response to mechanical stretching caused by stiffer failing myocardium16. On 
the other hand, although we did not observe differences in abundance of circulating Ly6Chi 
between groups, the chemokine receptor profile on these cells differed. In control animals, 
Ly6Chi monocytes shown increased expression of CX3CR1 and CCR2 receptors at 14 days, 
and of CCR2 up to day 28 post-I/R. This phenotype could have facilitated their extravasation 
and differentiation into macrophages in the ischemic hearts121. It has been proposed that the 
presence of macrophages in the remote zone of infarcted myocardium correlates with 
adverse heart remodeling via ECM turnover and fibroblast proliferation122. Therefore, a 
lower amount of cardiac macrophages in the remote zone of VEGF/S1P-treated hearts might 
be both a cause and a result of better-preserved heart outcome.   
Finally, we wanted to know if the BMhVEGF/BMhSphK1 therapy caused changes in the heart 
vasculature. Thanks to the automated analysis method developed in our lab, we were able to 
have a deeper look at the alterations in post-ischemic myocardium. Structural analysis of the 
infarct zone vasculature revealed that even though overall vascular density was the same in 
control and treated hearts, in the former large vessel volume density was higher while in the 
latter capillary volume density was higher. Moreover, in the remote zone, we observed a 
similar trend, although the difference in capillary volume density was not significant. 
Observed changes suggest that the vascular network in the treated hearts was better 
preserved, which could be further confirmed by a strong trend towards a lower degree of 
heterogeneity in the gap sizes described as lacunarity. It has been demonstrated that in 
response to shear and/or metabolic stress, blood vessels increase their diameter123. In our 
experimental setting, we observed higher amounts of large vessels in the infarct and remote 
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zones of untreated animals, which might suggest angioadaptation in response to insufficient 
blood supply. On the other hand, the increased amount of capillaries in treated hearts 
suggests better preservation of the vascular network and, therefore, no need for vasodilation 
in these hearts. Equal distribution of non-vascularized areas ensures proper oxygenation of 
the surrounding tissue; and, in addition to lacunarity, maximal extravascular distance can be 
used to describe the oxygenation potential of tissue. This distance was shorter in both the 
infarct and remote zones of treated hearts, suggesting better oxygenation. Furthermore, in 
the infarct zone of treated hearts, we observed a higher amount of endothelial cells per 
vascular volume although still lower than in the remote zone. In various previously-tested 
proangiogenic therapies, including AAV-mediated overexpression of VEGF and Ang1 in a 
pig model of MI 60, plasmid-mediated overexpression of bFBF and PDGF in a rat model of 
MI125, and microcapsule  release of FGF2 and HGF in a rat model of HF126, improvement in 
cardiac vasculature was observed. In these trials, both capillary and arteriole/large vessel 
content was increased, the latter of which we believe is an angioadaptative response to 
impaired capillarization of the tissue. This assumption is supported by the fact that in our 
VEGF/S1P-treated hearts, higher capillary content was associated with a smaller maximal 
intravascular distance and lower lacunarity.  
Despite the fact that the adult mammalian heart has a limited ability to regenerate, it has 
been shown that there is very restricted, but constant, cardiomyocyte proliferation over the 
lifespan of the organism (approximately 1% of cardiomyocytes annually)127,128. It was also 
demonstrated that this ability increases to over 3% in the border zone over 8 weeks after 
MI127. Therefore, a stable and functional vasculature is of great importance to keep these 
cardiomyocytes alive and to preserve cardiac function. In addition, despite the proangiogenic 
effect of BMhVEGF/BMhSphK1 therapy, S1P may play an important role in the overall 
improvement observed in this study. Expression of both sphingosine kinase isoforms 
(SphK1 and SphK2) was described in cardiac fibroblasts and cardiomyocytes which are an 
important source of endogenous S1P in the heart129. It has been shown that S1P generation 
in the heart increases in response to transient ischemia, suggesting its beneficial role in pre- 
and post-conditioning phenomena130. Cardiomyocytes predominantly express the S1P1131, 
which is involved in hypertrophic response and cardiac protection, because cardiomyocyte-
restricted depletion of S1P1 caused progressive cardiomyopathy and premature death of 
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mutant mice29. In the same study, the ischemic preconditioning effect was abolished in 
S1P1αMHCCre mice, suggesting that S1P1 plays a role in this mechanism. Furthermore, S1P 
signaling seems to be involved in pathological remodeling of the remote zone of the heart 
post-MI. In a porcine model of MI, delivery of fingolimod, a functional agonist of S1P 
receptors, reduced infarct size, improved cardiac function, and ameliorated pathological 
cardiac remodeling132. These beneficial effects were explained by the activation of protective 
pathways against ischemia-reperfusion injury, the RISK (Reperfusion Injury Salvage 
Kinase) and SAFE (Survivor Activating Factor Enhancement) pathways. The beneficial role 
of S1P in reducing infarct size via these pathways was also demonstrated in a ex vivo isolated 
Langendorff heart model of myocardial infarction133.  
In this study, we performed an I/R model of MI and our final time-point was 4 weeks 
after MI. However, to access global changes in the heart geometry (e.g. left ventricle 
remodeling) 4 weeks might not have been enough. In a permanent LAD ligation model of 
MI, the main changes in cardiac parameters occur within the first month post-MI112. On the 
other hand, in a 30-minute I/R model in mice, it was shown that between 2 and 8 weeks after 
MI, end diastolic and systolic volumes kept increasing, while the ejection fraction remained 
unchanged134. Therefore, we propose that in future experiments the timeline be expanded to 
at least 8 weeks to allow for further development of the HF phenotype and to observe the 
beneficial effects of the therapy.  
We believe there are a few questions in this study requiring further elucidation. One of 
them is the abovementioned prolongation of the study to see an impact of the therapy on 
preventing remodeling and subsequent heart failure. We observed favorable features in 
treated hearts (i.e., prevented cardiomyocyte hypertrophy, preserved heart shape, a trend 
towards preservation of left ventricle volumes), but we cannot come to definitive 
conclusions, since we are not sure if the final phenotype was achieved in the control hearts. 
To confirm or exclude developing of HF in these mice, lung analysis for the presence of 
edema and/or pulmonary hypertension might be useful.  
In our study, gene-cell therapy was compared to a placebo (PBS) to acquire a clear 
determination of its efficacy. However, a comparison with wild type BM or mock-infected 
BM could have helped to establish the precise contribution of paracrine signaling by the BM 
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cells and of the VEGF/S1P proangiogenic factors delivered. In terms of global left ventricle 
function, clinical trials using intracoronary injection of whole BM showed no long-term 
improvement in LVEF after MI38,40, despite promising short-term effects37,135. However, 
these trials did not assess the pro-angiogenic effect of the cells. Yoon et al, demonstrated 
that selective elimination of endothelium-committed BM cells previously transplanted into 
ischemic myocardium decreased LVEF and reduced capillary and arteriole density at 4 
weeks post-MI compared to whole GFP-BM. In this experimental setting, although it showed 
a trend, treatment with GFP-BM did not significantly increase capillary or SMA+ density 
compared to PBS treated mice136. This result resembles our in vitro study, where treatment 
with wild type BM cells only slightly increased aortic ring sprouting. Therefore, since the 
effect of whole BM remains undetermined and there are studies showing an improvement in 
vascularization after whole BM cell treatment of MI137,138, it would have been informative 
to have included this control group in our study. 
It would also be interesting to perform a more robust study of the homing of 
intravenously-injected cells by injecting BM cells with lentivirally-induced overexpression 
of luciferase together with GFP. This would allow for in vivo tracking of cell distribution 
after intravenous injection in infarcted mice using the IVIS system. This way, we could 
examine if cells home on to organs other than the heart, and the duration of their presence in 
vivo. It would also allow for the determination of whether lentivirally-infected BM cells 
home only to the ischemic tissue or if they enter the remote zone of the heart as well.  
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CONCLUSIONS  
1. Lentiviral (LV) infection of mouse bone marrow cells is an efficient system for 
inducing their secretion of the human proangiogenic factors VEGF-A (VEGF), 
angiopoietin-1 (Ang1), and sphingosine-1-phosphate (S1P).  
2. The most efficient combination of proangiogenic factors in vitro is the sequential 
delivery of VEGF and S1P or S1P alone, compared with VEGF plus Ang1 or these 
factors separately.  
3. Sequential delivery of VEGF and S1P by mouse bone marrow cells is also the 
optimal combination to induce angiogenesis in vitro.  
4. Lentiviral infection of bone marrow cells shifts their phenotype increasing neutrophil 
abundance and inducing higher monocytes expression of the chemokine receptor 
CX3CR1. 
5. Sequential VEGF/S1P gene-cell therapy by intravenous injection on LV-infected 
bone marrow cells positively impacts cardiac performance by inducing mild 
improvement of pump function and ameliorating adverse remodeling after 
ischemia/reperfusion in mice compared with control. 
6. Sequential VEGF/S1P gene-cell therapy also ameliorates the inflammatory 
monocyte response observed in control mice, favoring healing and decreasing 
macrophage abundance in the remote zone. 
7. As primarily aimed, sequential VEGF/S1P gene-cell therapy enhances capillary 
density, decreases adverse angioadaptation and reduces extravascular distances in the 
infarcted zone, resulting in overall better oxygenation of the heart. 
8. Despite no major reduction in scar size, sequential VEGF/S1P gene-cell therapy 
leads to a lower damage index (myofibroblast density) in the infarcted area, 
indicating milder fibrosis. 
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